MeSH term
Frequency | Condition_Probility | Aged | 381 | 1.0 |
Aged, 80 and over | 62 | 0.0 |
Fatal Outcome | 4 | 0.0 |
Female | 1446 | 1.0 |
Humans | 3557 | 1.0 |
Child | 412 | 3.0 |
Environment | 2 | 2.0 |
Male | 1333 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 771 | 1.0 |
Adolescent | 503 | 2.0 |
Child, Preschool | 219 | 2.0 |
Cyclosporine/adverse effects | 2 | 12.0 |
Diagnosis, Differential | 7 | 0.0 |
Animals | 291 | 0.0 |
Antibodies, Monoclonal | 59 | 2.0 |
*Cytotoxicity, Immunologic | 73 | 15.0 |
Flow Cytometry | 71 | 1.0 |
Gene Expression | 31 | 0.0 |
HLA Antigens/analysis/genetics/*physiology | 2 | 100.0 |
Immunosorbent Techniques | 11 | 3.0 |
Killer Cells, Natural/*immunology | 30 | 6.0 |
Mice | 165 | 0.0 |
Neoplasms/*immunology | 10 | 9.0 |
Pregnancy | 163 | 2.0 |
Rats | 12 | 0.0 |
Research Support, Non-U.S. Gov't | 1634 | 1.0 |
*Signal Transduction | 2 | 0.0 |
Transfection | 69 | 0.0 |
Tumor Cells, Cultured | 98 | 0.0 |
Arthritis, Juvenile Rheumatoid/*genetics | 4 | 23.0 |
Gene Frequency | 391 | 8.0 |
Genetic Predisposition to Disease | 60 | 2.0 |
HLA-A Antigens/*genetics | 184 | 92.0 |
HLA-DQ Antigens/genetics | 56 | 21.0 |
HLA-DR Antigens/genetics | 106 | 27.0 |
Haplotypes | 172 | 8.0 |
Linkage Disequilibrium | 53 | 6.0 |
Microsatellite Repeats | 14 | 1.0 |
Phenotype | 324 | 3.0 |
Telomere/*genetics | 4 | 10.0 |
Cell Line | 265 | 1.0 |
RNA, Messenger/analysis | 15 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
Alleles | 398 | 5.0 |
Case-Control Studies | 41 | 0.0 |
Chromosome Mapping | 131 | 1.0 |
Comparative Study | 453 | 1.0 |
Cross Reactions | 74 | 9.0 |
Disease Susceptibility | 73 | 10.0 |
HLA Antigens/*analysis | 340 | 79.0 |
HLA-A Antigens/analysis | 76 | 83.0 |
HLA-A1 Antigen/analysis | 2 | 100.0 |
HLA-A2 Antigen/analysis | 10 | 71.0 |
HLA-A3 Antigen/analysis | 5 | 100.0 |
HLA-B Antigens/analysis | 79 | 73.0 |
HLA-B35 Antigen/analysis | 2 | 66.0 |
HLA-B7 Antigen/analysis | 2 | 50.0 |
HLA-DR Antigens/analysis | 81 | 12.0 |
HLA-DR1 Antigen/analysis | 2 | 28.0 |
HLA-DR4 Antigen/analysis | 9 | 50.0 |
Likelihood Functions | 9 | 5.0 |
Statistics | 18 | 3.0 |
English Abstract | 265 | 2.0 |
Graft Rejection/*immunology | 13 | 16.0 |
*Lymphocyte Culture Test, Mixed | 23 | 40.0 |
Swine | 5 | 0.0 |
Bone Marrow Transplantation | 14 | 5.0 |
Evaluation Studies | 19 | 2.0 |
*Genes, MHC Class I | 131 | 51.0 |
HLA-B Antigens/analysis/*genetics/immunology | 2 | 50.0 |
Nucleic Acid Hybridization/*methods | 2 | 4.0 |
Polymerase Chain Reaction/methods | 31 | 2.0 |
Quality Control | 5 | 2.0 |
Registries | 52 | 23.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 102 | 1.0 |
Sensitivity and Specificity | 26 | 0.0 |
Sequence Analysis, DNA/methods | 4 | 4.0 |
Serologic Tests/methods | 2 | 15.0 |
Histocompatibility Antigens Class I/*genetics | 99 | 30.0 |
*Linkage (Genetics) | 44 | 3.0 |
Pan troglodytes/*genetics | 4 | 14.0 |
Pedigree | 180 | 2.0 |
Polymorphism, Single-Stranded Conformational | 18 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
Amino Acid Sequence | 180 | 0.0 |
Base Sequence | 242 | 0.0 |
Genes, MHC Class I | 40 | 32.0 |
HLA Antigens/genetics | 89 | 29.0 |
Histocompatibility Antigens Class I/*biosynthesis/*genetics | 2 | 50.0 |
Molecular Sequence Data | 287 | 0.0 |
RNA, Messenger/metabolism | 16 | 0.0 |
Sequence Alignment | 29 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Transcription, Genetic | 25 | 0.0 |
Alaska/ethnology | 3 | 50.0 |
*Alleles | 139 | 10.0 |
HLA Antigens/classification/*genetics | 8 | 72.0 |
HLA-A Antigens/classification/genetics | 6 | 100.0 |
HLA-B Antigens/classification/genetics | 7 | 87.0 |
HLA-C Antigens/classification/genetics | 7 | 100.0 |
HLA-DQ Antigens/classification/genetics | 3 | 75.0 |
HLA-DR Antigens/classification/genetics | 2 | 66.0 |
Homozygote | 74 | 3.0 |
Immunophenotyping | 38 | 1.0 |
Inuits/*genetics | 2 | 15.0 |
Polymorphism, Genetic | 128 | 2.0 |
Adult | 1012 | 1.0 |
*Genetic Predisposition to Disease | 15 | 1.0 |
HLA Antigens/*blood | 19 | 70.0 |
Histocompatibility Antigens Class I/blood | 2 | 25.0 |
Histocompatibility Testing | 402 | 50.0 |
Leprosy/*genetics/immunology | 4 | 50.0 |
Middle Aged | 724 | 1.0 |
Odds Ratio | 23 | 2.0 |
Turkey | 3 | 2.0 |
Biopsy | 23 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 6 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 10 | 3.0 |
Cells, Cultured | 123 | 0.0 |
Immunoenzyme Techniques | 45 | 1.0 |
Mice, SCID | 3 | 0.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 25 | 0.0 |
Epitopes | 135 | 15.0 |
Immunotherapy/methods | 3 | 3.0 |
Interferon Type II/metabolism | 3 | 1.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Peptides/chemistry | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*metabolism | 3 | 14.0 |
HLA-A Antigens/*genetics/*immunology | 4 | 100.0 |
Evolution, Molecular | 11 | 1.0 |
Morocco | 2 | 12.0 |
*Polymorphism, Genetic | 93 | 2.0 |
DNA/*genetics | 12 | 3.0 |
DNA Probes | 13 | 1.0 |
Genes, MHC Class I/*genetics | 36 | 50.0 |
Genotype | 162 | 1.0 |
*Hematopoietic Stem Cell Transplantation | 23 | 5.0 |
Predictive Value of Tests | 15 | 0.0 |
*T-Lymphocytes, Cytotoxic | 2 | 28.0 |
Tissue Donors | 113 | 42.0 |
China | 20 | 4.0 |
DNA/genetics | 31 | 1.0 |
DNA Probes/genetics | 2 | 1.0 |
Nucleic Acid Hybridization/methods | 3 | 4.0 |
Polymerase Chain Reaction/*methods | 31 | 5.0 |
B-Lymphocytes/*immunology | 66 | 8.0 |
Graft Rejection/immunology | 13 | 20.0 |
HLA-A Antigens/immunology | 50 | 72.0 |
HLA-B Antigens/immunology | 47 | 74.0 |
Infant | 142 | 2.0 |
Kidney Transplantation/*immunology | 73 | 35.0 |
T-Lymphocytes/immunology | 54 | 3.0 |
Transplantation Immunology/*immunology | 3 | 42.0 |
Transplantation, Homologous | 135 | 20.0 |
Treatment Outcome | 77 | 2.0 |
United States | 49 | 5.0 |
DNA, Complementary | 16 | 0.0 |
HLA-C Antigens/*genetics | 35 | 52.0 |
Cross-Sectional Studies | 8 | 0.0 |
*Kidney Transplantation | 174 | 36.0 |
Lymphocyte Activation | 81 | 2.0 |
T-Lymphocytes/*immunology | 102 | 4.0 |
Blood Group Incompatibility | 2 | 15.0 |
Living Donors | 16 | 36.0 |
Survival Analysis | 65 | 2.0 |
Age Factors | 65 | 2.0 |
Cohort Studies | 22 | 0.0 |
Cryopreservation | 3 | 2.0 |
Europe | 25 | 8.0 |
*Heart Transplantation | 6 | 7.0 |
Histocompatibility | 70 | 66.0 |
*Lung Transplantation | 4 | 14.0 |
Reoperation | 16 | 12.0 |
Time Factors | 110 | 1.0 |
Bone Marrow/*immunology | 7 | 11.0 |
*Bone Marrow Transplantation | 81 | 21.0 |
HLA Antigens/*genetics/immunology | 24 | 57.0 |
HLA-A Antigens/genetics/immunology | 18 | 90.0 |
HLA-B Antigens/genetics/immunology | 17 | 68.0 |
HLA-DR Antigens/*genetics/immunology | 5 | 9.0 |
*Haplotypes | 44 | 17.0 |
Histocompatibility Testing/*methods | 90 | 59.0 |
Immunogenetics | 20 | 40.0 |
Italy | 43 | 6.0 |
Rural Population | 2 | 2.0 |
*Tissue Donors | 71 | 52.0 |
Anemia, Aplastic/therapy | 7 | 46.0 |
Bone Marrow Transplantation/*immunology | 46 | 38.0 |
Genetic Diseases, Inborn/therapy | 4 | 66.0 |
Graft vs Host Disease/immunology/prevention & control | 3 | 42.0 |
Graft vs Leukemia Effect/immunology | 2 | 50.0 |
HLA-B Antigens/*genetics | 113 | 41.0 |
HLA-DR Antigens/*genetics | 56 | 10.0 |
Immunosuppressive Agents/therapeutic use | 20 | 9.0 |
Lymphoma/therapy | 2 | 20.0 |
Myelodysplastic Syndromes/therapy | 4 | 23.0 |
Recurrence | 42 | 3.0 |
Retrospective Studies | 111 | 3.0 |
Hemochromatosis/complications/epidemiology/*genetics | 2 | 66.0 |
Mutation | 38 | 0.0 |
Autoimmune Diseases/*genetics | 4 | 9.0 |
Chronic Disease | 56 | 3.0 |
Japan | 83 | 5.0 |
Gene Frequency/*genetics | 13 | 9.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Haplotypes/genetics | 35 | 6.0 |
Histocompatibility Antigens Class II/*genetics | 61 | 32.0 |
Linkage Disequilibrium/genetics | 10 | 6.0 |
Turkey/epidemiology | 4 | 5.0 |
*Algorithms | 7 | 11.0 |
Cadaver | 98 | 41.0 |
Continental Population Groups | 20 | 11.0 |
Follow-Up Studies | 91 | 2.0 |
Graft Survival/*immunology | 27 | 48.0 |
Histocompatibility Antigens Class I/immunology | 15 | 14.0 |
Immunosuppression | 18 | 10.0 |
Prospective Studies | 53 | 1.0 |
Fluorescein Angiography | 2 | 1.0 |
Codon/genetics | 4 | 1.0 |
HLA Antigens/genetics/immunology | 16 | 53.0 |
Hematologic Neoplasms/therapy | 2 | 8.0 |
Incidence | 28 | 2.0 |
Proportional Hazards Models | 25 | 3.0 |
*Transplantation, Homologous | 4 | 36.0 |
Tumor Necrosis Factor-alpha/*genetics | 8 | 2.0 |
Amino Acids/analysis | 4 | 1.0 |
Antibody Specificity | 63 | 4.0 |
HLA-A Antigens/genetics | 128 | 81.0 |
HLA-B Antigens/genetics | 118 | 56.0 |
HLA-C Antigens/genetics | 57 | 59.0 |
Down-Regulation | 20 | 1.0 |
Gene Expression Profiling | 4 | 0.0 |
Golgi Apparatus/physiology | 2 | 25.0 |
HLA Antigens/*immunology | 201 | 71.0 |
HLA-C Antigens/*immunology | 8 | 57.0 |
Histocompatibility Antigens Class I/*immunology | 34 | 30.0 |
Killer Cells, Natural/immunology | 17 | 4.0 |
T-Lymphocytes, Cytotoxic/immunology | 32 | 8.0 |
HLA Antigens/*genetics | 501 | 59.0 |
HLA-DR Antigens/genetics/metabolism | 2 | 18.0 |
Histocompatibility Antigens Class I/genetics | 20 | 20.0 |
*Loss of Heterozygosity | 4 | 1.0 |
RNA, Messenger/genetics | 23 | 0.0 |
RNA, Neoplasm/genetics | 5 | 1.0 |
Acute Disease | 60 | 2.0 |
Fathers | 4 | 6.0 |
HLA Antigens/*blood/*genetics | 3 | 100.0 |
Histocompatibility Testing/methods | 26 | 59.0 |
Infant, Newborn | 56 | 1.0 |
Leukemia/surgery | 4 | 40.0 |
Mothers | 2 | 2.0 |
*Blood Donors | 17 | 15.0 |
HLA Antigens/*analysis/genetics | 75 | 75.0 |
Hepatitis B Surface Antigens/*blood | 2 | 22.0 |
Senegal/epidemiology | 3 | 25.0 |
Adjuvants, Immunologic/*therapeutic use | 2 | 2.0 |
Disease-Free Survival | 23 | 2.0 |
Histocompatibility Antigens Class I/*metabolism | 12 | 12.0 |
Antigens, Neoplasm/*genetics | 3 | 4.0 |
Chromosomes, Human, Pair 6/genetics | 11 | 9.0 |
Genes, MHC Class I/genetics | 6 | 26.0 |
HLA-A2 Antigen/*genetics | 10 | 58.0 |
Karyotyping | 12 | 0.0 |
Melanoma/*genetics/immunology | 4 | 40.0 |
Polymerase Chain Reaction | 147 | 1.0 |
Sequence Analysis, DNA | 27 | 0.0 |
Age of Onset | 13 | 1.0 |
Genes, MHC Class II | 67 | 28.0 |
Japan/epidemiology | 11 | 3.0 |
Introns | 4 | 0.0 |
*Linkage Disequilibrium | 16 | 9.0 |
Arthritis, Rheumatoid/epidemiology/*genetics | 2 | 33.0 |
HLA-D Antigens/*genetics | 35 | 23.0 |
HLA-DP Antigens/genetics | 12 | 24.0 |
Risk Factors | 129 | 2.0 |
Histocompatibility Antigens Class II/genetics | 46 | 38.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
Polymorphism, Restriction Fragment Length | 52 | 2.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
*Evolution, Molecular | 19 | 4.0 |
France | 18 | 6.0 |
*Variation (Genetics) | 21 | 2.0 |
Interferon Type II/secretion | 3 | 2.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Autoantibodies/*blood | 3 | 1.0 |
Diabetes Mellitus, Type 1/*genetics/*immunology | 3 | 13.0 |
HLA-DQ Antigens/*genetics | 16 | 4.0 |
HLA-DR3 Antigen/*genetics | 5 | 17.0 |
HLA-DR4 Antigen/*genetics | 2 | 6.0 |
Islets of Langerhans/immunology | 4 | 10.0 |
Amino Acid Substitution | 3 | 0.0 |
Brazil/epidemiology | 2 | 2.0 |
Genetic Screening | 5 | 0.0 |
Hemochromatosis/epidemiology/*genetics | 4 | 30.0 |
Heterozygote | 50 | 1.0 |
*Membrane Proteins | 11 | 1.0 |
Mutation/*genetics | 5 | 0.0 |
Prevalence | 19 | 1.0 |
Gene Expression Regulation, Neoplastic/*immunology | 4 | 26.0 |
Transcription, Genetic/*immunology | 3 | 9.0 |
Abortion, Spontaneous/immunology | 2 | 25.0 |
Antibodies, Blocking/pharmacology | 2 | 2.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
*Antigen Presentation | 4 | 2.0 |
Antigens, CD/biosynthesis/immunology | 2 | 7.0 |
Cell Adhesion/immunology | 2 | 1.0 |
Choriocarcinoma/immunology | 2 | 50.0 |
K562 Cells | 8 | 1.0 |
*Lectins, C-Type | 6 | 3.0 |
Macromolecular Substances | 24 | 1.0 |
Data Collection | 2 | 2.0 |
Graft Survival/immunology | 22 | 41.0 |
Graft vs Host Disease/epidemiology/immunology | 2 | 100.0 |
Multivariate Analysis | 30 | 2.0 |
Nuclear Family | 13 | 5.0 |
Cause of Death | 11 | 6.0 |
Graft Survival | 148 | 38.0 |
Graft vs Host Disease | 7 | 28.0 |
*Histocompatibility | 37 | 71.0 |
Graft vs Host Reaction/immunology | 2 | 40.0 |
HLA-C Antigens/genetics/immunology | 7 | 50.0 |
*Histocompatibility Testing | 159 | 75.0 |
Biological Markers/analysis | 5 | 0.0 |
Chorionic Villi/immunology | 4 | 30.0 |
DNA/analysis | 24 | 2.0 |
Histocompatibility Antigens Class I/analysis | 12 | 12.0 |
Immunohistochemistry | 34 | 0.0 |
Pregnancy Trimester, First | 6 | 2.0 |
Trophoblasts/*cytology/immunology | 3 | 75.0 |
African Continental Ancestry Group/*genetics | 20 | 7.0 |
Blotting, Western | 4 | 0.0 |
Models, Molecular | 13 | 0.0 |
Protein Binding | 22 | 0.0 |
Protein Conformation | 29 | 0.0 |
Structure-Activity Relationship | 16 | 0.0 |
Graft vs Host Disease/etiology/*immunology/mortality | 2 | 100.0 |
Haplotypes/immunology | 7 | 50.0 |
Histocompatibility/immunology | 6 | 75.0 |
*Immune Tolerance | 13 | 7.0 |
Leukemia/complications/mortality/therapy | 2 | 50.0 |
Maternal-Fetal Exchange/*immunology | 5 | 29.0 |
Antilymphocyte Serum/*therapeutic use | 5 | 17.0 |
Drug Resistance | 6 | 0.0 |
European Continental Ancestry Group/genetics | 36 | 5.0 |
HLA-A1 Antigen/*genetics | 4 | 57.0 |
DNA Primers | 35 | 0.0 |
HLA-C Antigens/analysis | 39 | 81.0 |
Kidney Transplantation | 15 | 12.0 |
Sampling Studies | 3 | 1.0 |
France/ethnology | 4 | 10.0 |
Genetic Markers | 88 | 3.0 |
Celiac Disease/*genetics | 6 | 21.0 |
*Family | 4 | 10.0 |
Genetic Predisposition to Disease/*genetics | 6 | 1.0 |
Haplotypes/*genetics | 22 | 11.0 |
Microsatellite Repeats/genetics | 8 | 2.0 |
Chi-Square Distribution | 24 | 3.0 |
DNA Mutational Analysis | 6 | 0.0 |
Spain/epidemiology | 2 | 1.0 |
Binomial Distribution | 2 | 25.0 |
Confidence Intervals | 7 | 2.0 |
HLA-B27 Antigen/genetics | 4 | 25.0 |
HLA-DR4 Antigen/genetics | 7 | 24.0 |
Immunosuppressive Agents/*adverse effects | 2 | 5.0 |
Liver Transplantation/*immunology | 5 | 16.0 |
Complement 4/*analysis | 5 | 10.0 |
HLA-A Antigens/*analysis | 36 | 100.0 |
HLA-B Antigens/*analysis | 45 | 88.0 |
Major Histocompatibility Complex/*genetics | 24 | 15.0 |
Mexico/ethnology | 7 | 25.0 |
Electrophoresis, Polyacrylamide Gel | 37 | 1.0 |
HLA-DP Antigens/*analysis | 2 | 33.0 |
HLA-DR Antigens/*analysis | 55 | 31.0 |
Research Design | 2 | 2.0 |
HLA Antigens/metabolism | 7 | 21.0 |
Histocompatibility Antigens Class I/metabolism | 3 | 4.0 |
Macrophages/*metabolism | 2 | 0.0 |
Colitis, Ulcerative/*immunology | 5 | 13.0 |
Colon/*immunology | 3 | 13.0 |
HLA-A Antigens/genetics/*immunology | 12 | 92.0 |
Intestinal Mucosa/*immunology | 5 | 5.0 |
T-Lymphocytes, Cytotoxic/*immunology | 90 | 17.0 |
Tissue Donors/*statistics & numerical data | 3 | 42.0 |
*Gene Frequency | 62 | 11.0 |
*Genetics, Population | 28 | 7.0 |
Tunisia | 5 | 11.0 |
Bone Marrow/immunology | 7 | 5.0 |
HLA-A Antigens/*genetics/immunology | 18 | 94.0 |
HLA-B Antigens/*genetics/immunology | 11 | 40.0 |
Bone Marrow Transplantation/*adverse effects | 5 | 10.0 |
Graft vs Host Disease/etiology | 19 | 34.0 |
Herpesvirus 4, Human | 9 | 6.0 |
*Lymphocyte Transfusion | 2 | 7.0 |
Immunity, Natural/genetics | 2 | 3.0 |
Tuberculosis, Pulmonary/*genetics | 2 | 22.0 |
Double-Blind Method | 9 | 0.0 |
Serologic Tests | 10 | 12.0 |
ATP-Binding Cassette Transporters/genetics/*metabolism | 3 | 5.0 |
CD8-Positive T-Lymphocytes/immunology | 8 | 1.0 |
Cell Division | 21 | 0.0 |
Clone Cells | 29 | 2.0 |
Cytotoxicity, Immunologic | 72 | 7.0 |
HLA-A2 Antigen/immunology | 2 | 5.0 |
Interleukin-2/metabolism | 2 | 1.0 |
Isoantigens/*immunology | 9 | 12.0 |
Phylogeny | 31 | 2.0 |
Species Specificity | 20 | 0.0 |
Terminology | 4 | 2.0 |
Antilymphocyte Serum/immunology | 8 | 61.0 |
Consanguinity | 12 | 3.0 |
HLA-C Antigens/immunology | 16 | 76.0 |
HLA-DR Antigens/immunology | 39 | 18.0 |
Lupus Erythematosus, Systemic/*genetics | 3 | 5.0 |
Spouses | 3 | 30.0 |
Hepatitis B Antibodies/analysis | 4 | 22.0 |
Hepatitis B Surface Antigens/analysis | 6 | 11.0 |
Hepatitis B Vaccines/*immunology | 2 | 15.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Drug Therapy, Combination | 6 | 0.0 |
*Graft Survival | 77 | 53.0 |
HLA-A Antigens/blood | 8 | 72.0 |
HLA-B Antigens/blood | 10 | 83.0 |
Histocompatibility Antigens Class I/blood/*genetics | 3 | 50.0 |
Iron/blood | 9 | 9.0 |
*Mutation | 13 | 0.0 |
Cell Communication | 3 | 1.0 |
Decidua/immunology | 3 | 37.0 |
Histocompatibility Antigens Class I/*analysis | 24 | 51.0 |
Immunity, Cellular | 20 | 3.0 |
Lymphocytes/immunology | 75 | 18.0 |
Placenta/cytology/*immunology | 2 | 28.0 |
Trophoblasts/immunology | 8 | 25.0 |
Genes, MHC Class I/*immunology | 9 | 40.0 |
Leukemia, Myeloid, Chronic/mortality/therapy | 2 | 100.0 |
Logistic Models | 6 | 0.0 |
Risk | 57 | 6.0 |
*Transplantation Immunology | 17 | 39.0 |
Antigen-Presenting Cells/immunology | 7 | 2.0 |
Antigens, Viral/immunology | 12 | 10.0 |
Cytotoxicity, Immunologic/*genetics | 2 | 22.0 |
Epitopes, T-Lymphocyte/immunology | 3 | 3.0 |
HLA-A2 Antigen/genetics/immunology | 3 | 50.0 |
HLA-B Antigens/genetics/*immunology | 10 | 52.0 |
Influenza A virus/*immunology | 3 | 18.0 |
Lymphocyte Count | 6 | 0.0 |
T-Lymphocytes, Cytotoxic/cytology/*immunology | 4 | 23.0 |
Epitopes/immunology | 27 | 5.0 |
Interferon Type II/biosynthesis | 5 | 1.0 |
Major Histocompatibility Complex | 31 | 13.0 |
Variation (Genetics) | 36 | 2.0 |
Cell Line, Transformed | 32 | 2.0 |
Exons | 24 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 3 | 1.0 |
*Cysteine Endopeptidases | 3 | 6.0 |
Gene Frequency/genetics | 20 | 4.0 |
Korea | 13 | 6.0 |
*Multienzyme Complexes | 4 | 5.0 |
Proteins/*genetics | 5 | 0.0 |
Antigens, Surface/genetics | 5 | 10.0 |
DNA, Complementary/genetics | 9 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
Neoplasm Staging | 10 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Phosphoglucomutase/genetics | 2 | 4.0 |
HLA-C Antigens/*analysis | 5 | 71.0 |
Abortion, Habitual/genetics/*immunology | 5 | 50.0 |
HLA-A Antigens/*blood/genetics | 2 | 100.0 |
HLA-B Antigens/*blood/genetics | 2 | 100.0 |
HLA-C Antigens/*blood/genetics | 2 | 100.0 |
Genetic Heterogeneity | 6 | 2.0 |
Psoriasis/*genetics | 4 | 6.0 |
Leukemia, Myeloid, Chronic/mortality/*therapy | 3 | 100.0 |
Life Tables | 13 | 7.0 |
Registries/statistics & numerical data | 4 | 30.0 |
Tissue and Organ Procurement | 17 | 77.0 |
Transplantation Conditioning | 8 | 14.0 |
United States/epidemiology | 7 | 1.0 |
HLA Antigens/*genetics/*immunology | 2 | 33.0 |
HLA-DQ Antigens/genetics/immunology | 5 | 25.0 |
HLA-DR Antigens/genetics/immunology | 9 | 27.0 |
Amniotic Fluid/*cytology/immunology | 2 | 100.0 |
Fetal Blood/*immunology | 7 | 8.0 |
Hematopoietic Stem Cell Transplantation/*methods | 2 | 2.0 |
Asian Continental Ancestry Group/genetics | 18 | 5.0 |
Thailand | 10 | 6.0 |
HLA-DR2 Antigen/*genetics | 3 | 15.0 |
Trinucleotide Repeats | 2 | 1.0 |
HLA-A Antigens/*immunology | 66 | 77.0 |
HLA-B Antigens/*immunology | 45 | 73.0 |
HLA-DR Antigens/*immunology | 44 | 34.0 |
*Keratoplasty, Penetrating | 2 | 33.0 |
*DNA Methylation | 3 | 0.0 |
Exons/genetics | 11 | 0.0 |
Graft vs Host Disease/genetics | 2 | 40.0 |
Transplantation Immunology/*genetics | 2 | 100.0 |
Transplantation, Homologous/immunology | 9 | 21.0 |
Point Mutation/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 17 | 1.0 |
Gene Frequency/*immunology | 5 | 62.0 |
Haplotypes/*immunology | 6 | 24.0 |
Histocompatibility Testing/statistics & numerical data | 3 | 75.0 |
DNA Methylation | 2 | 0.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
*Genes, MHC Class II | 53 | 17.0 |
Hela Cells | 11 | 0.0 |
Interferon Type II/pharmacology | 21 | 3.0 |
*Nuclear Proteins | 4 | 0.0 |
Promoter Regions (Genetics) | 11 | 0.0 |
CpG Islands | 2 | 0.0 |
DNA Primers/chemistry | 8 | 0.0 |
Gene Deletion | 9 | 0.0 |
Histocompatibility Antigens Class I/*genetics/metabolism | 4 | 21.0 |
Loss of Heterozygosity | 5 | 0.0 |
HLA Antigens/*analysis/immunology | 10 | 55.0 |
Histocompatibility Antigens Class II/analysis | 56 | 28.0 |
*Immunity | 2 | 4.0 |
Virus Diseases/immunology | 3 | 15.0 |
Bone Marrow Transplantation/adverse effects/*immunology | 6 | 75.0 |
Graft vs Host Disease/etiology/immunology | 3 | 75.0 |
*HLA-C Antigens | 8 | 57.0 |
HLA-DQ Antigens | 10 | 31.0 |
HLA-DR Antigens | 204 | 58.0 |
In Vitro | 41 | 0.0 |
Isoantigens | 6 | 22.0 |
T-Lymphocytes, Helper-Inducer/immunology | 7 | 3.0 |
Autoantibodies/blood | 3 | 1.0 |
Blood Pressure | 2 | 0.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
Echocardiography | 4 | 1.0 |
Heart Valve Prosthesis Implantation | 2 | 15.0 |
Histocompatibility/*immunology | 14 | 93.0 |
Alternative Splicing | 5 | 0.0 |
Gorilla gorilla | 5 | 12.0 |
Models, Genetic | 23 | 1.0 |
Pan troglodytes/*immunology | 2 | 33.0 |
Repetitive Sequences, Nucleic Acid | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 34 | 1.0 |
Anemia, Aplastic/*therapy | 7 | 63.0 |
Antilymphocyte Serum/administration & dosage | 3 | 60.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Immunosuppressive Agents/administration & dosage | 6 | 23.0 |
*Salvage Therapy | 2 | 9.0 |
Whole-Body Irradiation | 11 | 13.0 |
Cytotoxicity Tests, Immunologic | 94 | 22.0 |
Spondylitis, Ankylosing/*genetics/immunology | 2 | 22.0 |
*Liver Transplantation | 8 | 5.0 |
*Living Donors | 9 | 47.0 |
African Continental Ancestry Group/genetics | 22 | 7.0 |
Ethnic Groups/*genetics | 24 | 12.0 |
Genetic Markers/genetics | 7 | 1.0 |
Indians, North American/genetics | 7 | 17.0 |
Asia, Southeastern | 2 | 10.0 |
Asian Continental Ancestry Group/*genetics | 11 | 3.0 |
HLA-D Antigens/genetics | 7 | 17.0 |
Indians, North American/*genetics | 12 | 14.0 |
Complement 4b/genetics | 2 | 9.0 |
Complement Factor B/genetics | 12 | 17.0 |
Indians, South American/*genetics | 18 | 27.0 |
Linguistics | 2 | 50.0 |
Venezuela | 8 | 25.0 |
Genes, MHC Class II/*genetics | 9 | 13.0 |
Blood Transfusion | 41 | 22.0 |
Graft vs Host Disease/*etiology | 5 | 41.0 |
Aging/*immunology | 4 | 3.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
HLA-A Antigens/*biosynthesis/genetics | 5 | 100.0 |
HLA-B Antigens/*biosynthesis/genetics | 4 | 100.0 |
Leukocytes/*immunology | 13 | 9.0 |
Centromere/genetics | 3 | 4.0 |
Chromosome Mapping/*methods | 5 | 2.0 |
HLA-A1 Antigen/genetics | 2 | 40.0 |
HLA-B8 Antigen/genetics | 5 | 27.0 |
HLA-DR3 Antigen/genetics | 3 | 12.0 |
Linkage Disequilibrium/*genetics | 3 | 4.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Antigens, CD4/metabolism | 3 | 0.0 |
Gene Products, nef/*metabolism | 2 | 7.0 |
HIV-1/metabolism | 2 | 4.0 |
HLA-A Antigens/*metabolism | 8 | 80.0 |
HLA-B Antigens/*metabolism | 6 | 50.0 |
Antibodies/*analysis | 11 | 10.0 |
Antibody Formation | 26 | 5.0 |
Graft Rejection/epidemiology/*immunology | 2 | 66.0 |
Graft Survival/*physiology | 3 | 15.0 |
Immunization | 32 | 8.0 |
Ethnic Groups/genetics | 12 | 6.0 |
Mexico/epidemiology | 2 | 6.0 |
Alu Elements/*genetics | 2 | 6.0 |
HLA-DR Antigens/genetics/*immunology | 5 | 15.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
HLA Antigens/*classification | 5 | 100.0 |
HLA-C Antigens/genetics/*immunology | 6 | 54.0 |
Histocompatibility Antigens Class I/genetics/immunology | 3 | 20.0 |
*Point Mutation | 3 | 0.0 |
Prognosis | 64 | 1.0 |
Remission Induction | 8 | 1.0 |
Transplantation, Autologous | 6 | 1.0 |
Biological Markers | 11 | 0.0 |
Complement 3/analysis | 6 | 1.0 |
Complement 4/analysis | 7 | 3.0 |
Solubility | 28 | 2.0 |
Cytotoxicity Tests, Immunologic/*methods | 4 | 40.0 |
Kidney Transplantation/immunology | 8 | 14.0 |
T-Lymphocytes, Cytotoxic/*immunology/pathology | 2 | 16.0 |
HLA-A Antigens/analysis/*genetics | 7 | 77.0 |
HLA-B Antigens/analysis/*genetics | 8 | 57.0 |
HLA-DR Antigens/analysis/*genetics | 2 | 15.0 |
Reference Values | 37 | 0.0 |
Sweden | 10 | 4.0 |
Hematologic Neoplasms/mortality/therapy | 3 | 50.0 |
Hematologic Neoplasms/complications/mortality/therapy | 2 | 66.0 |
DNA/*analysis | 8 | 3.0 |
Graft Rejection/*prevention & control | 7 | 16.0 |
Graft vs Host Disease/*prevention & control | 5 | 18.0 |
Leukemia, Lymphocytic, Acute/therapy | 2 | 20.0 |
Leukemia, Myelocytic, Acute/therapy | 3 | 23.0 |
Leukemia, Myeloid, Chronic/therapy | 3 | 21.0 |
HLA Antigens/immunology | 86 | 47.0 |
Histocompatibility Antigens Class I/classification/*genetics | 6 | 54.0 |
HLA-B35 Antigen/genetics | 3 | 50.0 |
HLA-B7 Antigen/genetics | 6 | 50.0 |
HLA-DR2 Antigen/genetics | 4 | 22.0 |
HLA-DR5 Antigen/genetics | 3 | 60.0 |
Polymorphism, Genetic/*immunology | 5 | 15.0 |
Antilymphocyte Serum/therapeutic use | 6 | 28.0 |
*Bone Marrow Transplantation/mortality | 4 | 44.0 |
Dose-Response Relationship, Radiation | 3 | 0.0 |
Graft vs Host Disease/mortality/prevention & control | 2 | 66.0 |
Infection/etiology/mortality | 2 | 40.0 |
Radiotherapy Dosage | 3 | 2.0 |
Salvage Therapy | 2 | 2.0 |
Survival Rate | 61 | 2.0 |
T-Lymphocytes | 5 | 2.0 |
Graft vs Host Disease/epidemiology | 7 | 58.0 |
Metabolism, Inborn Errors/therapy | 3 | 100.0 |
Coculture Techniques | 3 | 0.0 |
HLA Antigens/analysis | 107 | 43.0 |
Hepacivirus/*immunology | 2 | 6.0 |
Culture | 2 | 13.0 |
Animals, Wild/*microbiology/parasitology/*virology | 2 | 40.0 |
Bacterial Infections/transmission/veterinary | 2 | 40.0 |
*Disease Reservoirs | 2 | 8.0 |
Parasitic Diseases/transmission | 2 | 40.0 |
Parasitic Diseases, Animal/transmission | 2 | 40.0 |
Prion Diseases/transmission/veterinary | 2 | 40.0 |
Virus Diseases/transmission/veterinary | 2 | 40.0 |
Zoonoses/*transmission | 2 | 40.0 |
Alkaline Phosphatase/metabolism | 3 | 2.0 |
Binding Sites | 25 | 0.0 |
Lymphocytes/immunology/metabolism | 4 | 12.0 |
Peptide Library | 2 | 1.0 |
beta 2-Microglobulin/metabolism | 10 | 12.0 |
DNA/genetics/isolation & purification | 3 | 1.0 |
Data Interpretation, Statistical | 6 | 2.0 |
European Continental Ancestry Group/*genetics | 19 | 5.0 |
Ireland | 6 | 11.0 |
Viral Load | 5 | 0.0 |
Lymphocyte Depletion/methods | 2 | 40.0 |
Binding, Competitive | 36 | 1.0 |
Epitopes/chemistry/*immunology | 2 | 10.0 |
HT29 Cells | 2 | 1.0 |
Graft vs Host Disease/*immunology | 7 | 25.0 |
HLA-DP Antigens/*genetics | 9 | 10.0 |
HLA-B Antigens/classification/*genetics | 9 | 52.0 |
Blood Group Incompatibility/*immunology | 2 | 28.0 |
Graft vs Host Disease/immunology | 5 | 16.0 |
Survivors | 2 | 2.0 |
HLA Antigens/classification/genetics | 2 | 66.0 |
Histocompatibility Antigens Class II/classification/*genetics | 2 | 50.0 |
Mexico | 8 | 8.0 |
Plasmodium falciparum/*immunology | 2 | 4.0 |
Blotting, Southern | 22 | 0.0 |
Cell Adhesion | 8 | 0.0 |
DNA, Viral/analysis | 3 | 0.0 |
Gene Rearrangement | 3 | 0.0 |
Immunoglobulins/biosynthesis | 2 | 1.0 |
Sex Factors | 49 | 3.0 |
HLA-A Antigens/blood/*genetics | 3 | 100.0 |
*Registries | 19 | 41.0 |
Reproducibility of Results | 14 | 0.0 |
Africa/ethnology | 5 | 10.0 |
Polymorphism, Genetic/genetics | 12 | 1.0 |
Cyclosporine/therapeutic use | 10 | 14.0 |
Hematologic Diseases/mortality/*therapy | 2 | 66.0 |
Cross Reactions/immunology | 3 | 6.0 |
Antipsychotic Agents/*adverse effects/therapeutic use | 2 | 16.0 |
Clozapine/*adverse effects/therapeutic use | 2 | 50.0 |
Antigen Presentation | 7 | 2.0 |
Antigens, CD/analysis | 8 | 0.0 |
Antigens, CD80/analysis | 2 | 4.0 |
Antigens, Neoplasm/immunology | 9 | 6.0 |
Fluorescent Dyes | 3 | 0.0 |
Melanoma/*immunology | 24 | 28.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Greece | 20 | 23.0 |
Mediterranean Region | 3 | 14.0 |
Antigen Presentation/genetics | 4 | 17.0 |
*Organ Transplantation | 2 | 9.0 |
Oligonucleotide Probes | 21 | 3.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
Blood Donors | 19 | 9.0 |
Gene Expression Regulation | 17 | 0.0 |
HLA-A Antigens/genetics/metabolism | 5 | 100.0 |
HLA-B Antigens/genetics/metabolism | 2 | 100.0 |
*Promoter Regions (Genetics) | 6 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Alternative Splicing/immunology | 2 | 28.0 |
Gene Expression Regulation/immunology | 5 | 3.0 |
Half-Life | 3 | 0.0 |
Interferon Type II/*pharmacology | 15 | 3.0 |
*Bone Marrow Transplantation/immunology | 7 | 43.0 |
Hematologic Neoplasms/immunology/*therapy | 2 | 40.0 |
Lymphocyte Culture Test, Mixed | 123 | 19.0 |
Binding Sites, Antibody | 15 | 4.0 |
DNA/*classification | 2 | 100.0 |
Binding Sites/genetics/immunology | 4 | 9.0 |
Chickens/*genetics/*immunology | 2 | 25.0 |
Cloning, Molecular | 48 | 0.0 |
Genetic Markers/immunology | 5 | 26.0 |
Multigene Family/*immunology | 2 | 8.0 |
*Polymorphism, Restriction Fragment Length | 14 | 1.0 |
Argentina | 4 | 8.0 |
Nucleic Acid Conformation | 4 | 0.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
Polymorphism, Genetic/immunology | 5 | 20.0 |
DNA/blood | 5 | 3.0 |
Epitopes/*genetics | 4 | 13.0 |
Antibodies, Monoclonal/analysis | 3 | 3.0 |
Gene Expression Regulation, Neoplastic/immunology | 4 | 14.0 |
HLA Antigens/*biosynthesis/genetics/immunology | 2 | 100.0 |
beta 2-Microglobulin/genetics/immunology | 2 | 40.0 |
Hemochromatosis/diagnosis/*genetics | 3 | 42.0 |
Spain | 14 | 4.0 |
Italy/epidemiology | 9 | 4.0 |
Graft Rejection/etiology | 4 | 50.0 |
Geography | 4 | 6.0 |
Hemochromatosis/*genetics | 30 | 30.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Mutation/genetics | 3 | 0.0 |
Population Dynamics | 2 | 25.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Variation (Genetics)/*genetics | 5 | 2.0 |
Family | 21 | 5.0 |
Gene Frequency/immunology | 3 | 20.0 |
Linkage Disequilibrium/*immunology | 2 | 50.0 |
Alzheimer Disease/*genetics | 3 | 0.0 |
Genes, MHC Class II/genetics | 4 | 14.0 |
Statistics, Nonparametric | 2 | 0.0 |
Hypersensitivity, Delayed/*immunology | 3 | 8.0 |
Immunologic Memory | 7 | 2.0 |
Isoantigens/immunology | 12 | 13.0 |
Lymphocyte Transfusion | 2 | 7.0 |
Postoperative Period | 5 | 1.0 |
Sequence Analysis, Protein | 2 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
T-Lymphocytes/chemistry | 2 | 6.0 |
Cytokines/*secretion | 3 | 5.0 |
HLA Antigens/genetics/*metabolism | 3 | 25.0 |
Histocompatibility Antigens Class I/genetics/*metabolism | 5 | 17.0 |
Interleukin-10/secretion | 2 | 6.0 |
Leukocytes, Mononuclear/*immunology | 8 | 4.0 |
Maternal-Fetal Exchange/immunology | 3 | 18.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/secretion | 2 | 1.0 |
HLA-C Antigens/*analysis/genetics | 2 | 100.0 |
Serotyping | 6 | 2.0 |
Immunosuppressive Agents/pharmacology | 3 | 1.0 |
Killer Cells, Natural/cytology/*immunology | 4 | 14.0 |
Cell Differentiation | 27 | 0.0 |
Chromatography, Affinity | 4 | 0.0 |
*Membrane Glycoproteins | 5 | 0.0 |
*Epitopes, T-Lymphocyte | 2 | 20.0 |
HIV/*immunology | 2 | 1.0 |
Staining and Labeling | 3 | 0.0 |
Amniotic Fluid/immunology | 2 | 33.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
Brazil | 18 | 7.0 |
*Ethnic Groups | 15 | 14.0 |
False Positive Reactions | 3 | 1.0 |
HLA-A Antigens/*analysis/genetics | 10 | 100.0 |
HLA-B Antigens/*analysis/genetics | 9 | 81.0 |
*Polymerase Chain Reaction | 13 | 6.0 |
*Serology | 2 | 66.0 |
Tissue and Organ Procurement/*methods | 4 | 50.0 |
Analysis of Variance | 9 | 0.0 |
Platelet Count | 5 | 1.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
*Down-Regulation | 4 | 1.0 |
*Enhancer Elements (Genetics) | 2 | 0.0 |
HLA-A2 Antigen/genetics | 6 | 42.0 |
*Transcription, Genetic | 8 | 0.0 |
T-Lymphocytes, Helper-Inducer/cytology | 2 | 22.0 |
Algorithms | 12 | 3.0 |
Epitopes/genetics/immunology | 4 | 10.0 |
Fluorescent Antibody Technique | 51 | 1.0 |
Combined Modality Therapy | 6 | 0.0 |
Cytomegalovirus Infections/epidemiology | 2 | 22.0 |
Ethnic Groups | 21 | 8.0 |
Hematologic Diseases/therapy | 5 | 62.0 |
Leukemia/therapy | 9 | 24.0 |
Computer Simulation | 5 | 1.0 |
*Models, Genetic | 4 | 3.0 |
*Selection (Genetics) | 7 | 10.0 |
Korea/epidemiology | 3 | 5.0 |
Prednisone/administration & dosage/therapeutic use | 3 | 27.0 |
Severity of Illness Index | 6 | 0.0 |
Cameroon | 2 | 9.0 |
Africa | 6 | 6.0 |
HLA-A Antigens/*classification/*genetics | 4 | 100.0 |
Indians, North American | 3 | 9.0 |
*Gene Deletion | 3 | 0.0 |
Lymph Nodes/pathology | 4 | 1.0 |
Major Histocompatibility Complex/*genetics/immunology | 3 | 33.0 |
Seroepidemiologic Studies | 3 | 2.0 |
Antigens, Viral/*immunology | 4 | 4.0 |
Cytomegalovirus/immunology | 3 | 4.0 |
Epitopes, T-Lymphocyte/*immunology | 4 | 6.0 |
Influenza A virus/immunology | 2 | 15.0 |
Hematopoietic Stem Cells/*immunology | 9 | 6.0 |
Europe/ethnology | 8 | 8.0 |
Fetal Blood/cytology | 4 | 2.0 |
Graft vs Host Disease/prevention & control | 10 | 17.0 |
Great Britain | 10 | 4.0 |
Tissue and Organ Procurement/*organization & administration | 10 | 90.0 |
*Graft Rejection | 21 | 23.0 |
Interleukin-6/secretion | 2 | 3.0 |
Histocompatibility Antigens Class I/*physiology | 6 | 28.0 |
Signal Transduction | 4 | 0.0 |
Virus Replication | 4 | 0.0 |
*Blood Group Incompatibility | 2 | 33.0 |
Bone Marrow | 2 | 5.0 |
Probability | 24 | 3.0 |
*Gene Expression | 8 | 0.0 |
RNA Splicing | 4 | 0.0 |
RNA, Messenger | 4 | 0.0 |
Antigen-Antibody Reactions | 20 | 5.0 |
beta 2-Microglobulin/*metabolism | 3 | 7.0 |
Electrophoresis, Agar Gel | 9 | 1.0 |
Slovakia | 2 | 9.0 |
Genetics, Population | 27 | 6.0 |
Registries/*statistics & numerical data | 5 | 16.0 |
DNA Primers/genetics | 9 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 8 | 5.0 |
Proteins/genetics/metabolism | 2 | 1.0 |
Germany | 7 | 2.0 |
IgA Deficiency/*genetics/*immunology | 2 | 66.0 |
Antigens/*analysis | 5 | 5.0 |
Antigens, CD3/immunology | 2 | 0.0 |
Cell Membrane/immunology/metabolism | 3 | 2.0 |
Temperature | 5 | 0.0 |
*Fetal Blood | 3 | 6.0 |
Graft Rejection/epidemiology | 6 | 27.0 |
*Kidney Transplantation/mortality/statistics & numerical data | 2 | 50.0 |
Endoplasmic Reticulum/metabolism | 3 | 1.0 |
Receptors, Immunologic/immunology | 2 | 1.0 |
*Blood Transfusion | 37 | 33.0 |
Graft Survival/drug effects | 6 | 20.0 |
Adenocarcinoma/genetics/immunology | 2 | 50.0 |
Cell Line, Tumor | 4 | 0.0 |
Neoplasm Metastasis | 6 | 0.0 |
Hematopoietic Stem Cell Transplantation/*methods/mortality | 4 | 50.0 |
Transplantation Immunology | 19 | 29.0 |
Graft vs Host Disease/*etiology/immunology | 2 | 66.0 |
Transplantation Chimera | 2 | 5.0 |
In Situ Hybridization | 4 | 0.0 |
Binding, Competitive/immunology | 3 | 3.0 |
Hydrolysis | 2 | 0.0 |
*Immune Tolerance/drug effects | 2 | 40.0 |
Immunoblotting | 7 | 0.0 |
Lipopolysaccharides/*immunology | 3 | 4.0 |
European Continental Ancestry Group | 51 | 8.0 |
Bone Marrow Transplantation/immunology | 9 | 24.0 |
HLA-A Antigens/*analysis/*genetics | 2 | 100.0 |
Histocompatibility Testing/methods/*standards | 2 | 100.0 |
Nucleic Acid Hybridization | 22 | 1.0 |
Interferon Type I, Recombinant/pharmacology | 6 | 18.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Fetus/immunology | 8 | 22.0 |
HLA Antigens/biosynthesis/genetics/*immunology | 2 | 66.0 |
Immune Tolerance/*immunology | 2 | 4.0 |
Neoplasms/immunology | 4 | 7.0 |
Organ Specificity | 6 | 0.0 |
T-Lymphocytes, Cytotoxic | 2 | 9.0 |
Trophoblasts/immunology/metabolism | 3 | 60.0 |
Graft Rejection | 45 | 30.0 |
HLA-DR Antigens/analysis/genetics | 8 | 30.0 |
Kidney/immunology | 15 | 36.0 |
India | 21 | 6.0 |
Treatment Failure | 7 | 2.0 |
Leukemia/mortality/*therapy | 7 | 87.0 |
Sweden/epidemiology | 2 | 1.0 |
B-Lymphocytes/immunology | 61 | 8.0 |
CD4-Positive T-Lymphocytes/immunology | 5 | 0.0 |
Langerhans Cells/immunology | 2 | 5.0 |
Macrophages/immunology | 5 | 1.0 |
Major Histocompatibility Complex/immunology | 5 | 10.0 |
Skin/immunology | 5 | 5.0 |
beta 2-Microglobulin/biosynthesis | 3 | 25.0 |
*Major Histocompatibility Complex | 79 | 26.0 |
Evolution | 17 | 4.0 |
Asian Continental Ancestry Group | 13 | 4.0 |
Angiotensin II Type 1 Receptor Blockers/*therapeutic use | 2 | 25.0 |
Benzimidazoles/*therapeutic use | 2 | 16.0 |
Hypertension/*prevention & control | 2 | 20.0 |
Tetrazoles/*therapeutic use | 2 | 13.0 |
*Inuits | 2 | 20.0 |
China/ethnology | 12 | 6.0 |
*Chromosome Mapping | 36 | 2.0 |
*Sequence Deletion | 3 | 0.0 |
HLA Antigens/genetics/*isolation & purification | 2 | 100.0 |
Histocompatibility Antigens Class I/genetics/*isolation & purification | 2 | 100.0 |
HLA-DQ Antigens/analysis | 17 | 34.0 |
HLA-DR6 Antigen/analysis | 3 | 75.0 |
Histocompatibility Antigens Class I/*genetics/*immunology | 3 | 75.0 |
Histocompatibility Antigens Class II/*genetics/*immunology | 2 | 100.0 |
HLA-A Antigens/classification/*genetics | 12 | 100.0 |
*Introns | 5 | 2.0 |
Macaca mulatta | 7 | 1.0 |
Melanoma/*genetics | 2 | 1.0 |
Antibodies, Viral/blood | 2 | 1.0 |
*Tissue Donors/statistics & numerical data | 3 | 100.0 |
Wales | 3 | 17.0 |
*Chromosomes, Human, Pair 6 | 29 | 10.0 |
Microsatellite Repeats/*genetics | 5 | 1.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 2 | 5.0 |
Stomach Neoplasms/*immunology | 2 | 11.0 |
T-Lymphocytes, Cytotoxic/*immunology/metabolism | 4 | 11.0 |
Kidney Transplantation/*mortality | 5 | 55.0 |
Bronchiolitis/*genetics | 2 | 40.0 |
Chromosomes, Human, Pair 6/*genetics | 6 | 4.0 |
Linkage (Genetics)/*genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 3 | 1.0 |
Carcinoma, Squamous Cell/*genetics | 3 | 1.0 |
Antigens, Neoplasm/*analysis | 12 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Tumor Stem Cells/immunology | 2 | 15.0 |
Histocompatibility Testing/*statistics & numerical data | 4 | 80.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
HLA-A Antigens/biosynthesis/genetics | 5 | 83.0 |
HLA-B Antigens/biosynthesis/genetics | 4 | 100.0 |
HLA-C Antigens/biosynthesis/genetics | 2 | 66.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
*Blood Banks | 2 | 25.0 |
Continental Population Groups/genetics | 7 | 8.0 |
HLA-DR Antigens/blood | 5 | 9.0 |
Antigen Presentation/*immunology | 2 | 2.0 |
HLA-A2 Antigen/*immunology | 5 | 22.0 |
Mice, Transgenic | 5 | 0.0 |
Peptides/*immunology | 4 | 5.0 |
Antibodies/immunology | 8 | 2.0 |
Blood Grouping and Crossmatching | 17 | 24.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Histocompatibility Antigens Class I/*blood | 7 | 63.0 |
Biological Markers/blood | 6 | 0.0 |
Creatinine/blood | 7 | 2.0 |
Aging | 9 | 2.0 |
Sex Characteristics | 2 | 0.0 |
Netherlands/epidemiology | 3 | 2.0 |
Heterozygote Detection | 13 | 2.0 |
*HLA Antigens | 158 | 76.0 |
HLA-A Antigens | 278 | 92.0 |
HLA-B Antigens | 320 | 82.0 |
HLA-D Antigens | 3 | 33.0 |
HLA-A Antigens/*classification | 2 | 100.0 |
HLA-B Antigens/*classification | 2 | 66.0 |
Antigens, Neoplasm/*immunology | 11 | 6.0 |
HLA-A3 Antigen/genetics/immunology | 2 | 100.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 6 | 8.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Neoplasm Proteins/immunology | 4 | 11.0 |
T-Lymphocyte Subsets/*immunology | 4 | 0.0 |
Tissue Preservation | 3 | 10.0 |
Culture Techniques | 2 | 0.0 |
HLA-A Antigens/genetics/*metabolism | 4 | 80.0 |
Croatia | 5 | 13.0 |
Autoantibodies/*immunology | 2 | 0.0 |
*Cryopreservation | 3 | 4.0 |
Histocompatibility Antigens Class II/*immunology | 55 | 32.0 |
Cell Membrane/immunology | 29 | 11.0 |
Cloning, Molecular/*methods | 5 | 7.0 |
DNA, Complementary/*genetics | 3 | 1.0 |
*Bone Marrow/immunology | 2 | 100.0 |
HLA Antigens/*chemistry | 2 | 66.0 |
HLA-A Antigens/chemistry | 3 | 75.0 |
HLA-B Antigens/chemistry | 4 | 80.0 |
HLA-DR Antigens/chemistry | 2 | 50.0 |
*Corneal Transplantation | 13 | 59.0 |
Antibodies, Monoclonal/*immunology | 33 | 4.0 |
Antigens, CD/*immunology | 4 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 5 | 2.0 |
Methotrexate/therapeutic use | 4 | 6.0 |
Safety | 2 | 1.0 |
Transplantation, Homologous/*adverse effects | 2 | 33.0 |
3T3 Cells | 2 | 0.0 |
Biological Transport/genetics/immunology | 2 | 25.0 |
Down-Regulation/*immunology | 2 | 3.0 |
Protein Binding/genetics/immunology | 5 | 6.0 |
Vaccinia virus/genetics | 3 | 4.0 |
Genes, Regulator/genetics | 2 | 4.0 |
Linkage (Genetics) | 167 | 6.0 |
Asia/ethnology | 2 | 6.0 |
Histocompatibility Antigens Class II/*analysis | 61 | 54.0 |
Indonesia/ethnology | 2 | 33.0 |
Receptors, Immunologic/*genetics | 4 | 3.0 |
*Recombination, Genetic | 28 | 8.0 |
Histocompatibility Antigens Class I/*genetics/immunology | 11 | 42.0 |
Gene Transfer Techniques | 2 | 0.0 |
Melanoma/genetics/*immunology | 5 | 33.0 |
Emigration and Immigration | 8 | 16.0 |
Point Mutation | 6 | 0.0 |
*DNA Primers | 7 | 25.0 |
RNA, Viral/analysis | 2 | 0.0 |
*Sexual Partners | 2 | 22.0 |
Gorilla gorilla/*genetics/immunology | 2 | 100.0 |
Philippines | 3 | 10.0 |
*Phylogeny | 3 | 1.0 |
Ethiopia | 3 | 11.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
Interferon Type II/immunology | 3 | 3.0 |
Gene Amplification | 6 | 0.0 |
HLA-A Antigens/biosynthesis/*genetics | 2 | 100.0 |
Introns/*genetics | 5 | 2.0 |
Pseudogenes/*genetics | 2 | 2.0 |
beta 2-Microglobulin/biosynthesis/genetics | 2 | 50.0 |
Graft vs Host Disease/etiology/prevention & control | 3 | 75.0 |
Leukemia/*therapy | 6 | 5.0 |
HLA-C Antigens/*genetics/immunology | 3 | 100.0 |
*Histocompatibility Testing/methods | 10 | 83.0 |
Lymphocytes/metabolism | 5 | 2.0 |
Mitosis/*genetics | 2 | 5.0 |
DNA | 15 | 1.0 |
Exons/*genetics | 3 | 0.0 |
Behcet Syndrome/*genetics | 4 | 17.0 |
Saudi Arabia | 2 | 4.0 |
Bone Marrow Transplantation/*immunology/mortality | 2 | 100.0 |
Epitopes/genetics | 6 | 6.0 |
Minor Histocompatibility Antigens/*genetics | 2 | 33.0 |
Disease Susceptibility/immunology | 8 | 11.0 |
HLA-DQ Antigens/*analysis | 6 | 35.0 |
Hematologic Neoplasms/*therapy | 5 | 18.0 |
Dose-Response Relationship, Immunologic | 11 | 2.0 |
Parity | 9 | 8.0 |
HLA Antigens/isolation & purification | 3 | 75.0 |
Kidney Transplantation/*statistics & numerical data | 7 | 70.0 |
Antigen-Presenting Cells/*immunology | 2 | 1.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Electrocardiography | 5 | 1.0 |
Kidney/pathology | 3 | 2.0 |
*Bone Marrow Transplantation/immunology/mortality | 2 | 66.0 |
Immunosuppression/methods | 5 | 15.0 |
Cyclophosphamide/therapeutic use | 9 | 9.0 |
Leukocytes/immunology | 6 | 4.0 |
Autoimmune Diseases/*genetics/immunology | 2 | 11.0 |
HLA Antigens/*biosynthesis/genetics | 5 | 45.0 |
Histocompatibility Antigens Class I/*biosynthesis/genetics | 4 | 36.0 |
Neoplasms/genetics/*immunology | 2 | 40.0 |
Blood Group Antigens/genetics | 8 | 13.0 |
Erythrocytes/enzymology | 3 | 0.0 |
Minisatellite Repeats | 2 | 1.0 |
*Paternity | 17 | 22.0 |
*Indians, North American | 5 | 16.0 |
London | 2 | 8.0 |
Chorionic Villi/immunology/metabolism | 2 | 50.0 |
*Gene Expression Regulation | 14 | 0.0 |
Placenta/*immunology/metabolism | 2 | 100.0 |
Gene Library | 10 | 0.0 |
Genes, MHC Class I/*physiology | 3 | 37.0 |
Sequence Homology, Amino Acid | 24 | 0.0 |
Promoter Regions (Genetics)/immunology | 2 | 2.0 |
Trans-Activation (Genetics)/*immunology | 2 | 10.0 |
Cytoplasm/chemistry/immunology | 2 | 100.0 |
HIV-1/*immunology | 4 | 0.0 |
HLA Antigens/physiology | 2 | 20.0 |
HLA-A2 Antigen/metabolism | 2 | 12.0 |
HLA-C Antigens/physiology | 2 | 100.0 |
Schizophrenia/*genetics | 5 | 2.0 |
*Antigens, CD | 4 | 0.0 |
Cytomegalovirus/*immunology | 3 | 4.0 |
Receptors, Immunologic/*immunology | 6 | 5.0 |
*Bone Marrow Transplantation/adverse effects/mortality | 2 | 50.0 |
Graft vs Host Disease/epidemiology/etiology | 2 | 40.0 |
*Hematopoietic Stem Cell Transplantation/adverse effects | 4 | 11.0 |
Leukocyte Count | 10 | 0.0 |
Neutrophils | 2 | 2.0 |
Adjuvants, Immunologic/physiology | 2 | 4.0 |
Cell Division/immunology | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Interferon Type II/*physiology | 3 | 4.0 |
Ligands | 8 | 0.0 |
Phosphorylation | 5 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
African Continental Ancestry Group | 31 | 10.0 |
Japan/ethnology | 7 | 10.0 |
Korea/ethnology | 2 | 11.0 |
Isoelectric Focusing/methods | 4 | 13.0 |
Genes, Dominant | 8 | 0.0 |
Genes, MHC Class II/*immunology | 2 | 10.0 |
Histocompatibility Antigens Class I/biosynthesis/genetics | 2 | 28.0 |
Trophoblasts/*immunology | 12 | 36.0 |
South Dakota | 3 | 60.0 |
Population Surveillance | 2 | 1.0 |
Disability Evaluation | 2 | 5.0 |
Cornea/*immunology | 9 | 75.0 |
Corneal Transplantation/*immunology | 7 | 58.0 |
Reference Standards | 6 | 2.0 |
HLA-C Antigens/classification/*genetics | 2 | 40.0 |
HLA-A2 Antigen/classification/*genetics | 2 | 100.0 |
Fertilization in Vitro | 2 | 1.0 |
Fetal Blood/immunology | 3 | 4.0 |
Pregnancy/*immunology | 10 | 18.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Peptides/immunology | 2 | 1.0 |
SIV/*immunology | 4 | 14.0 |
beta 2-Microglobulin/*immunology | 13 | 52.0 |
Antibodies, Monoclonal/immunology | 52 | 3.0 |
HLA-A Antigens/genetics/immunology/*metabolism | 2 | 66.0 |
HLA-B Antigens/genetics/immunology/*metabolism | 3 | 100.0 |
Immunologic Surveillance | 2 | 7.0 |
Histocompatibility Testing/*methods/*standards | 2 | 66.0 |
World Health Organization | 3 | 3.0 |
Netherlands | 5 | 3.0 |
Bone Marrow Transplantation/*methods | 6 | 13.0 |
Hematopoietic Stem Cells/immunology | 9 | 11.0 |
Proteins/genetics | 2 | 0.0 |
Psoriasis/*genetics/*immunology | 3 | 37.0 |
beta 2-Microglobulin/genetics | 5 | 23.0 |
HLA-A Antigens/chemistry/*genetics | 2 | 100.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Trophoblasts/metabolism | 2 | 5.0 |
*Asian Continental Ancestry Group | 7 | 10.0 |
*Gene Conversion | 3 | 9.0 |
Retroviridae/*genetics/immunology | 2 | 100.0 |
Cattle | 11 | 0.0 |
Immunity, Cellular/*immunology | 2 | 7.0 |
Models, Immunological | 3 | 1.0 |
Oligopeptides/immunology | 2 | 11.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Poland/epidemiology | 3 | 5.0 |
*Bone Marrow Transplantation/adverse effects | 3 | 11.0 |
Taiwan | 14 | 7.0 |
ATP-Binding Cassette Transporters/genetics | 2 | 3.0 |
Histocompatibility Antigens Class I/analysis/*genetics | 2 | 50.0 |
Brain/pathology | 2 | 0.0 |
Matched-Pair Analysis | 2 | 2.0 |
Gene Products, gag/*immunology | 2 | 8.0 |
Semen/cytology/*immunology | 3 | 100.0 |
HLA Antigens | 68 | 52.0 |
Celiac Disease/*immunology | 4 | 21.0 |
Education | 2 | 12.0 |
Urban Population | 4 | 3.0 |
Gene Expression/drug effects | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 3 | 3.0 |
Databases, Factual | 6 | 2.0 |
Feasibility Studies | 4 | 1.0 |
Health Policy | 2 | 15.0 |
International Cooperation | 13 | 16.0 |
Histocompatibility Antigens Class II/*genetics/immunology | 4 | 20.0 |
Graft Rejection/epidemiology/immunology | 2 | 50.0 |
*Kidney Transplantation/immunology/statistics & numerical data | 2 | 66.0 |
Sequence Analysis, DNA/instrumentation/*methods | 2 | 40.0 |
Europe, Eastern/ethnology | 2 | 50.0 |
*Histocompatibility Antigens Class I | 4 | 36.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Immunomagnetic Separation | 2 | 1.0 |
Molecular Weight | 38 | 1.0 |
beta 2-Microglobulin/immunology | 21 | 61.0 |
Disease Progression | 7 | 0.0 |
*HIV-1 | 4 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
beta 2-Microglobulin/analysis | 15 | 11.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
HLA-B7 Antigen/*genetics | 4 | 57.0 |
*Repressor Proteins | 3 | 0.0 |
Pan troglodytes/genetics/immunology | 2 | 66.0 |
Family Health | 9 | 0.0 |
Glycoproteins/immunology | 6 | 7.0 |
Lod Score | 8 | 0.0 |
Skin Tests | 7 | 3.0 |
Antigens, CD/immunology | 4 | 0.0 |
Histocompatibility Antigens Class I/genetics/*immunology | 8 | 29.0 |
Russia | 5 | 5.0 |
Gene Conversion | 7 | 12.0 |
Recombination, Genetic | 56 | 6.0 |
HLA-DQ Antigens/immunology | 14 | 35.0 |
Asthma/*immunology | 4 | 4.0 |
Autoimmune Diseases/*immunology | 8 | 4.0 |
Hypersensitivity/*immunology | 5 | 10.0 |
HLA-B Antigens/genetics/*metabolism | 2 | 50.0 |
Melanoma/*immunology/metabolism | 3 | 23.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Histocompatibility Antigens Class II/genetics/immunology | 5 | 25.0 |
Cell Membrane/metabolism | 7 | 0.0 |
Isoelectric Focusing | 22 | 3.0 |
*Bone Marrow | 2 | 40.0 |
Czech Republic | 2 | 4.0 |
Heart Transplantation/*immunology | 8 | 12.0 |
Immunosuppressive Agents/*therapeutic use | 6 | 4.0 |
Myocardium/pathology | 2 | 2.0 |
France/epidemiology | 2 | 1.0 |
Lymphocyte Depletion | 6 | 3.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 4 | 2.0 |
HLA-A Antigens/metabolism | 7 | 53.0 |
HLA-B Antigens/metabolism | 5 | 50.0 |
HLA-C Antigens/*biosynthesis | 3 | 100.0 |
Lymphocytes | 6 | 3.0 |
Genome, Human | 2 | 0.0 |
Gorilla gorilla/genetics | 2 | 7.0 |
Pan troglodytes/genetics | 2 | 4.0 |
Liver Transplantation/adverse effects/*immunology | 2 | 66.0 |
RNA, Viral/blood | 4 | 0.0 |
Monocytes/immunology | 13 | 3.0 |
Canada/epidemiology | 2 | 5.0 |
Base Pair Mismatch | 2 | 1.0 |
HLA-A Antigens/analysis/genetics | 3 | 60.0 |
HLA-B Antigens/analysis/genetics | 3 | 50.0 |
HLA-C Antigens/analysis/genetics | 4 | 80.0 |
Histocompatibility Antigens Class I/*analysis/genetics | 5 | 71.0 |
Precipitin Tests | 17 | 0.0 |
Protein Precursors/*genetics | 2 | 1.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Calcium/metabolism | 4 | 0.0 |
Monocytes/*physiology | 2 | 1.0 |
Rabbits | 31 | 1.0 |
Receptors, Fc/*physiology | 2 | 5.0 |
Receptors, Immunologic/*physiology | 4 | 2.0 |
*Antibodies, Monoclonal | 19 | 7.0 |
Binding Sites/genetics | 2 | 0.0 |
Epitopes/chemistry/genetics | 2 | 9.0 |
HLA-B Antigens/chemistry/genetics | 2 | 66.0 |
HLA-DP Antigens/*immunology | 7 | 58.0 |
Heterosexuality | 2 | 10.0 |
Autoimmunity | 4 | 3.0 |
Histocompatibility Antigens Class II/*metabolism | 2 | 3.0 |
B-Lymphocytes | 10 | 5.0 |
Epitope Mapping | 5 | 1.0 |
Immunodominant Epitopes/immunology | 2 | 10.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Peptide Fragments/immunology | 7 | 3.0 |
Breast Neoplasms/*immunology | 4 | 7.0 |
Denmark/epidemiology | 2 | 3.0 |
Random Allocation | 9 | 1.0 |
*Serologic Tests | 4 | 40.0 |
Antilymphocyte Serum | 4 | 28.0 |
Blood Transfusion/*adverse effects | 9 | 14.0 |
HLA-D Antigens/immunology | 7 | 17.0 |
Isoantibodies/blood/*immunology | 2 | 66.0 |
Platelet Transfusion | 3 | 10.0 |
Melanoma, Experimental/*immunology | 2 | 28.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Biological Transport | 5 | 0.0 |
Hemochromatosis/diagnosis/*genetics/therapy | 2 | 100.0 |
Iron/blood/metabolism | 2 | 33.0 |
Mass Screening | 2 | 1.0 |
Phlebotomy | 2 | 8.0 |
HLA Antigens/genetics/*immunology | 47 | 64.0 |
*Software | 3 | 5.0 |
Antigens, Helminth/immunology | 2 | 6.0 |
Carcinoma/*immunology | 3 | 10.0 |
Colorectal Neoplasms/*immunology | 3 | 11.0 |
Computational Biology | 3 | 2.0 |
Antigens, Neoplasm/analysis | 11 | 3.0 |
Melanoma/*immunology/secondary | 3 | 42.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Linkage (Genetics)/genetics | 3 | 1.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 3 | 5.0 |
Syndrome | 6 | 0.0 |
*Genotype | 5 | 2.0 |
Leukemia, Myeloid, Chronic/*therapy | 3 | 21.0 |
Histocompatibility Antigens | 4 | 25.0 |
Indicators and Reagents | 4 | 1.0 |
Interleukin-2/biosynthesis | 5 | 1.0 |
*Genome, Human | 2 | 0.0 |
DNA/isolation & purification | 2 | 1.0 |
HLA-C Antigens/analysis/*genetics | 3 | 50.0 |
Sequence Analysis, DNA/*methods | 3 | 4.0 |
Binding Sites/immunology | 2 | 3.0 |
HLA-A2 Antigen/*metabolism | 2 | 25.0 |
Protein Binding/immunology | 5 | 2.0 |
Graft Survival/physiology | 6 | 37.0 |
*Cross Reactions | 5 | 35.0 |
*Epitopes | 32 | 23.0 |
International Agencies | 3 | 50.0 |
Washington | 3 | 23.0 |
Risk Assessment | 3 | 0.0 |
Abortion, Habitual/*genetics/immunology | 2 | 40.0 |
Complement 4a/*genetics | 3 | 8.0 |
Complement 4b/*genetics | 4 | 11.0 |
Complement Factor B/*genetics | 15 | 11.0 |
HLA Antigens/blood | 3 | 25.0 |
Antigens, CD34 | 2 | 0.0 |
Dendritic Cells/*cytology | 2 | 3.0 |
Hematopoietic Stem Cells/*cytology | 2 | 0.0 |
HLA Antigens/genetics/physiology | 2 | 50.0 |
Lupus Erythematosus, Systemic/ethnology/*genetics/immunology | 2 | 40.0 |
Interleukin-1/*biosynthesis | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 2 | 0.0 |
HLA-DQ Antigens/analysis/genetics | 5 | 62.0 |
Tuberculosis, Pulmonary/*immunology | 2 | 5.0 |
ABO Blood-Group System/immunology | 9 | 36.0 |
Blood Group Antigens/*immunology | 2 | 6.0 |
HLA-DR5 Antigen/analysis | 2 | 100.0 |
DNA Mutational Analysis/*methods | 2 | 1.0 |
Serology | 4 | 33.0 |
Age Distribution | 2 | 0.0 |
DNA Restriction Enzymes | 9 | 2.0 |
HLA-A Antigens/chemistry/genetics/*metabolism | 2 | 100.0 |
Models, Biological | 14 | 0.0 |
Cytomegalovirus Infections/immunology | 2 | 7.0 |
Hepatitis B/immunology | 2 | 18.0 |
HLA-B7 Antigen/classification/*genetics | 2 | 100.0 |
Immunity, Maternally-Acquired/*immunology | 2 | 50.0 |
HLA-A Antigens/*blood | 6 | 85.0 |
HLA-B Antigens/*blood | 6 | 75.0 |
HLA-DQ Antigens/*blood | 2 | 33.0 |
HLA-DR Antigens/*blood | 5 | 25.0 |
South Africa | 13 | 8.0 |
Meiosis | 5 | 4.0 |
Transferrin/analysis | 7 | 7.0 |
ATP-Binding Cassette Transporters/*metabolism | 2 | 2.0 |
HLA-C Antigens/*metabolism | 2 | 66.0 |
Peptides/metabolism | 2 | 0.0 |
Culture Media | 5 | 0.0 |
HLA-D Antigens/*immunology | 15 | 25.0 |
Lymphocyte Cooperation | 3 | 3.0 |
Mitogens/pharmacology | 5 | 1.0 |
T-Lymphocytes/*cytology | 2 | 2.0 |
Mice, Inbred DBA | 2 | 0.0 |
Mice, Inbred Strains | 7 | 0.0 |
Interleukin-2/*biosynthesis | 2 | 1.0 |
*Lymphocyte Activation/drug effects | 5 | 4.0 |
Stem Cells/immunology | 3 | 9.0 |
Transcription, Genetic/immunology | 2 | 2.0 |
Ireland/ethnology | 4 | 57.0 |
Cluster Analysis | 3 | 1.0 |
Regression Analysis | 7 | 0.0 |
Isoantibodies/*immunology | 10 | 26.0 |
Ferritin/blood | 4 | 2.0 |
Genomic Library | 3 | 0.0 |
H-2 Antigens/genetics | 6 | 24.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
*Microtubule-Associated Proteins | 2 | 2.0 |
Sequence Tagged Sites | 3 | 1.0 |
Carcinoma, Squamous Cell/immunology | 2 | 7.0 |
*Antigens, Neoplasm | 4 | 2.0 |
Melanoma/*metabolism | 3 | 4.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Uveal Neoplasms/*metabolism | 2 | 40.0 |
Antigens, Neoplasm/*analysis/genetics | 2 | 12.0 |
Histocompatibility Antigens Class II/*analysis/genetics | 4 | 50.0 |
Skin Neoplasms/immunology/pathology | 2 | 22.0 |
Complement/immunology | 6 | 6.0 |
Complement Fixation Tests | 6 | 6.0 |
Fever/etiology | 2 | 8.0 |
Isoantibodies/*analysis | 10 | 43.0 |
Platelet Transfusion/*adverse effects | 2 | 25.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Blood Platelets/*immunology | 14 | 17.0 |
HLA-A Antigens/*biosynthesis | 3 | 75.0 |
HLA-B Antigens/*biosynthesis | 3 | 75.0 |
Erythrocytes/*immunology | 9 | 4.0 |
HLA-C Antigens/blood | 3 | 60.0 |
Lymphocytes/*immunology | 54 | 13.0 |
HLA Antigens/analysis/genetics | 14 | 53.0 |
Major Histocompatibility Complex/genetics | 3 | 5.0 |
Program Evaluation | 3 | 7.0 |
India/ethnology | 4 | 5.0 |
Rheumatic Heart Disease/*genetics/immunology | 2 | 100.0 |
Fetal Blood/*cytology | 2 | 1.0 |
Algeria | 2 | 11.0 |
Portugal | 2 | 3.0 |
Spain/ethnology | 6 | 20.0 |
Forecasting | 6 | 1.0 |
HLA-DR Antigens/*analysis/genetics | 9 | 36.0 |
*Terminology | 3 | 5.0 |
DNA Probes, HLA/*genetics | 2 | 50.0 |
Diagnostic Errors | 4 | 5.0 |
DNA Probes, HLA | 7 | 36.0 |
*Sequence Analysis, DNA | 6 | 8.0 |
Preoperative Care | 15 | 9.0 |
Graft Rejection/*epidemiology | 2 | 50.0 |
Visual Acuity | 3 | 1.0 |
Population | 3 | 10.0 |
*European Continental Ancestry Group | 7 | 8.0 |
HLA-B8 Antigen/genetics/immunology | 2 | 66.0 |
Histocompatibility Testing/*standards | 6 | 85.0 |
Tissue and Organ Procurement/*standards | 2 | 100.0 |
Hong Kong | 5 | 10.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
Primates | 3 | 4.0 |
*Chromosome Deletion | 7 | 0.0 |
*Phenotype | 7 | 2.0 |
*Tissue Banks | 4 | 57.0 |
Marriage | 5 | 21.0 |
Selection (Genetics) | 10 | 7.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
Injections, Intralesional | 2 | 4.0 |
Cervix Neoplasms/*immunology | 3 | 15.0 |
Recombinant Proteins/biosynthesis/genetics | 2 | 2.0 |
*Genetic Markers | 13 | 3.0 |
Databases | 3 | 3.0 |
*Kidney Transplantation/immunology | 6 | 60.0 |
Outcome Assessment (Health Care) | 2 | 4.0 |
Genome | 4 | 1.0 |
*Multigene Family | 5 | 0.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
HLA-C Antigens/chemistry | 2 | 66.0 |
HLA-B27 Antigen/analysis | 5 | 23.0 |
Laryngeal Neoplasms/*immunology | 3 | 33.0 |
DNA, Satellite/*genetics | 4 | 6.0 |
Greece/ethnology | 3 | 15.0 |
HLA-DP Antigens/genetics/*immunology | 4 | 36.0 |
*Lymphocyte Activation | 38 | 2.0 |
Antibodies/analysis | 12 | 9.0 |
Cold | 9 | 7.0 |
Diabetes Mellitus/surgery | 2 | 66.0 |
HLA-DQ Antigens/*analysis/genetics | 3 | 18.0 |
Organ Preservation | 11 | 50.0 |
Longitudinal Studies | 3 | 0.0 |
Renal Dialysis | 12 | 3.0 |
Deoxyribonucleases, Type II Site-Specific | 3 | 1.0 |
Tyrosine/genetics | 2 | 4.0 |
North America | 7 | 12.0 |
*Indians, South American | 6 | 26.0 |
Marriage/*ethnology | 2 | 100.0 |
Founder Effect | 2 | 1.0 |
Haploidy | 44 | 37.0 |
Adenocarcinoma/*immunology | 5 | 12.0 |
Lung Neoplasms/*immunology/pathology | 3 | 23.0 |
Down-Regulation/immunology | 3 | 3.0 |
HLA-A Antigens/biosynthesis | 7 | 77.0 |
HLA-B Antigens/biosynthesis | 6 | 60.0 |
HLA-C Antigens/biosynthesis | 5 | 71.0 |
*Transplantation | 2 | 66.0 |
Major Histocompatibility Complex/genetics/immunology | 2 | 20.0 |
Mongolia/ethnology | 3 | 60.0 |
Immunosuppressive Agents/*administration & dosage | 3 | 10.0 |
Hemochromatosis/genetics | 8 | 22.0 |
Recombination, Genetic/*genetics | 3 | 4.0 |
Nucleic Acid Heteroduplexes | 2 | 4.0 |
*Lymphocyte Depletion | 4 | 5.0 |
T-Lymphocytes/cytology/*immunology | 3 | 2.0 |
Siberia | 3 | 7.0 |
Disease Models, Animal | 3 | 0.0 |
Hemochromatosis/*genetics/immunology | 4 | 44.0 |
Health Care Rationing | 2 | 66.0 |
Ischemia | 2 | 11.0 |
Waiting Lists | 7 | 33.0 |
Conserved Sequence | 3 | 0.0 |
Sequence Analysis | 6 | 1.0 |
Genetic Complementation Test | 5 | 0.0 |
*Antibody Specificity | 8 | 11.0 |
Transplantation, Homologous/*immunology | 4 | 15.0 |
Leukemia, Lymphocytic, Acute/mortality/therapy | 2 | 100.0 |
Leukemia, Lymphocytic, Acute/*therapy | 3 | 18.0 |
Leukemia, Myelocytic, Acute/*therapy | 4 | 17.0 |
Myelodysplastic Syndromes/*therapy | 2 | 14.0 |
Autoantigens/genetics | 2 | 5.0 |
Blotting, Northern | 16 | 0.0 |
Histones/genetics | 2 | 9.0 |
*RNA, Small Cytoplasmic | 4 | 15.0 |
Patient Selection | 2 | 1.0 |
Lymphocytes/chemistry/immunology | 2 | 50.0 |
Protein Denaturation | 2 | 0.0 |
Pilot Projects | 7 | 1.0 |
Linkage Disequilibrium/immunology | 3 | 50.0 |
Nigeria | 3 | 4.0 |
Stomach Neoplasms/genetics/*immunology | 2 | 40.0 |
Antigens, Neoplasm/metabolism | 2 | 2.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
*Tissue and Organ Procurement | 6 | 60.0 |
Genetic Markers/*genetics | 5 | 4.0 |
HLA Antigens/*physiology | 5 | 35.0 |
HLA-A Antigens/physiology | 2 | 100.0 |
HLA-B Antigens/physiology | 2 | 66.0 |
Macrophages/*immunology | 6 | 2.0 |
Immunosuppression/*methods | 2 | 8.0 |
Tissue Banks | 2 | 18.0 |
Epithelial Cells | 5 | 1.0 |
Histocompatibility Antigens Class I/*biosynthesis | 8 | 21.0 |
Trophoblasts/cytology/*metabolism | 2 | 9.0 |
Epithelium/immunology | 10 | 7.0 |
Histocompatibility Antigens Class I/immunology/*metabolism | 2 | 18.0 |
Lectins/*metabolism | 2 | 3.0 |
Killer Cells, Natural/immunology/*metabolism | 2 | 6.0 |
HLA Antigens/*metabolism | 10 | 30.0 |
Killer Cells, Natural/*metabolism | 4 | 6.0 |
*Receptors, Immunologic | 2 | 1.0 |
Leukemia, Lymphocytic, Acute, L1/*therapy | 2 | 25.0 |
History, 20th Century | 3 | 2.0 |
*Marriage | 2 | 40.0 |
Social Class | 3 | 8.0 |
Carcinoma, Non-Small-Cell Lung/*immunology | 3 | 37.0 |
Carcinoma, Squamous Cell/*immunology | 3 | 10.0 |
Interleukin-2/immunology | 2 | 1.0 |
Lung Neoplasms/*immunology | 5 | 10.0 |
Aging/*genetics | 2 | 3.0 |
Abortion, Habitual/*genetics/*immunology | 2 | 50.0 |
Liver/pathology | 2 | 1.0 |
ABO Blood-Group System | 15 | 24.0 |
Chromosomes, Artificial, Yeast/genetics | 2 | 1.0 |
Bone Marrow Cells | 5 | 1.0 |
Israel | 9 | 5.0 |
Hispanic Americans | 3 | 4.0 |
Pan troglodytes | 5 | 4.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
Antigens, Surface/analysis | 27 | 6.0 |
Mice, Nude | 6 | 0.0 |
Neoplasm Transplantation | 6 | 0.0 |
Transplantation, Heterologous | 6 | 0.0 |
Arthritis, Rheumatoid/*genetics | 4 | 5.0 |
Genes | 15 | 7.0 |
Methods | 5 | 2.0 |
HLA Antigens/*classification/*immunology | 2 | 100.0 |
HLA-A3 Antigen/genetics | 5 | 83.0 |
Kidney Failure, Chronic/*surgery | 2 | 40.0 |
Cell Membrane | 2 | 3.0 |
Arthritis, Rheumatoid/genetics/*immunology | 9 | 24.0 |
Regional Medical Programs/*organization & administration | 2 | 100.0 |
Southeastern United States | 4 | 40.0 |
*Continental Population Groups | 2 | 7.0 |
HLA Antigens/*classification/genetics | 2 | 50.0 |
Leukemia/genetics/*immunology | 3 | 60.0 |
H-2 Antigens/immunology | 3 | 14.0 |
Mice, Knockout | 2 | 0.0 |
Denmark | 13 | 8.0 |
Stem Cells/cytology/*immunology | 2 | 28.0 |
Arthritis, Rheumatoid/*genetics/immunology | 6 | 12.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Cardiomyopathy, Hypertrophic/*genetics/immunology | 4 | 100.0 |
Cell Fusion | 6 | 2.0 |
*Genes, myc | 2 | 0.0 |
Methylation | 6 | 1.0 |
Models, Theoretical | 3 | 2.0 |
Hematopoietic Stem Cell Transplantation | 3 | 1.0 |
Rheumatoid Factor/analysis | 6 | 9.0 |
Epitopes/*immunology | 11 | 5.0 |
Mice, Inbred BALB C | 16 | 0.0 |
Asthma/immunology | 2 | 5.0 |
HLA-A Antigens/analysis/immunology | 5 | 71.0 |
Hypersensitivity, Immediate/immunology | 2 | 9.0 |
Immune Tolerance/genetics | 2 | 20.0 |
Occupational Diseases/*immunology | 2 | 40.0 |
Oligonucleotide Probes/chemistry | 3 | 9.0 |
DNA, Recombinant | 6 | 3.0 |
HIV Envelope Protein gp41/*immunology | 2 | 9.0 |
HIV Infections/*immunology | 3 | 0.0 |
Simian Acquired Immunodeficiency Syndrome/*immunology | 3 | 16.0 |
Molecular Biology | 3 | 1.0 |
Cell Division/drug effects | 9 | 0.0 |
Histocompatibility Antigens Class II/genetics/*immunology | 8 | 27.0 |
Pseudogenes/genetics | 2 | 2.0 |
*Haploidy | 11 | 78.0 |
Lymphocyte Culture Test, Mixed/methods | 4 | 40.0 |
HLA-A3 Antigen/*immunology | 3 | 60.0 |
*Waiting Lists | 4 | 100.0 |
Antigen Presentation/*genetics | 2 | 11.0 |
Lymphocyte Activation/genetics | 2 | 2.0 |
Neoplasms, Germ Cell and Embryonal/*immunology | 2 | 50.0 |
Orthomyxoviridae/immunology | 3 | 15.0 |
*Hematopoiesis | 3 | 1.0 |
Costs and Cost Analysis | 2 | 3.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Romania | 2 | 11.0 |
Cell Survival | 6 | 0.0 |
Cyclosporine/administration & dosage | 2 | 22.0 |
*Meiosis | 2 | 6.0 |
Spermatozoa/*immunology | 6 | 14.0 |
Iron/metabolism | 2 | 1.0 |
Cell Movement | 2 | 0.0 |
Clone Cells/immunology | 24 | 15.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 2 | 3.0 |
Skin/immunology/pathology | 2 | 4.0 |
Carcinoma, Squamous Cell/*immunology/pathology | 4 | 28.0 |
Cervix Neoplasms/*immunology/pathology | 2 | 33.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
HLA Antigens/*biosynthesis | 9 | 45.0 |
Cloning, Molecular/methods | 2 | 1.0 |
*Oligonucleotide Probes | 2 | 8.0 |
Peptides/chemistry/*immunology | 3 | 23.0 |
Histocompatibility Antigens Class II/immunology | 35 | 19.0 |
HLA Antigens/analysis/immunology | 3 | 60.0 |
Isoelectric Point | 5 | 4.0 |
Tumor Cells, Cultured/immunology | 3 | 3.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Antibodies | 9 | 2.0 |
Cytotoxicity Tests, Immunologic/methods | 5 | 19.0 |
HLA-B8 Antigen/analysis | 3 | 100.0 |
Finland | 7 | 2.0 |
Canada | 5 | 3.0 |
Hepatitis Antibodies/blood | 2 | 16.0 |
Hepatitis B Surface Antigens/*immunology | 3 | 25.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Liver/cytology/immunology | 3 | 33.0 |
Myelodysplastic Syndromes/mortality/*therapy | 2 | 100.0 |
*Organ Preservation | 2 | 16.0 |
Uterine Neoplasms/*immunology | 4 | 40.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Cosmids | 5 | 1.0 |
DNA Fingerprinting | 3 | 2.0 |
Gambia | 2 | 5.0 |
Arizona/epidemiology | 2 | 16.0 |
Antigens, CD4 | 2 | 2.0 |
Kidney Transplantation/*physiology | 2 | 4.0 |
Influenza A Virus, Human/*immunology | 4 | 13.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Abortion, Habitual/*immunology | 11 | 45.0 |
Oligodeoxyribonucleotides | 5 | 0.0 |
DNA Fingerprinting/*methods | 2 | 3.0 |
Immunoglobulin Allotypes/*genetics | 6 | 27.0 |
Nucleic Acid Heteroduplexes/*genetics | 2 | 15.0 |
Diseases in Twins | 5 | 10.0 |
*Family Health | 2 | 3.0 |
HLA-DR2 Antigen/blood | 2 | 66.0 |
Chromosomes, Human, Pair 6 | 15 | 9.0 |
Repetitive Sequences, Nucleic Acid/genetics | 2 | 2.0 |
Lymphocyte Activation/*immunology | 3 | 0.0 |
HLA-A Antigens/*chemistry/genetics | 2 | 100.0 |
Models, Structural | 2 | 1.0 |
Protein Structure, Secondary | 2 | 0.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
*Histocompatibility Antigens Class II | 18 | 29.0 |
Blood Proteins/genetics | 2 | 3.0 |
Mice/genetics | 2 | 3.0 |
Open Reading Frames | 2 | 0.0 |
Gestational Age | 5 | 0.0 |
*Immunotherapy | 4 | 2.0 |
Consensus Sequence | 13 | 1.0 |
Cyclosporine/*administration & dosage | 2 | 28.0 |
Isoantibodies/immunology | 11 | 26.0 |
HLA-A3 Antigen | 11 | 91.0 |
HLA-B35 Antigen | 20 | 83.0 |
HLA-C Antigens | 122 | 91.0 |
HLA-DR3 Antigen | 24 | 61.0 |
Hepatitis B virus/immunology | 2 | 11.0 |
Placenta | 2 | 4.0 |
Graft vs Host Disease/epidemiology/prevention & control | 5 | 71.0 |
Complement 4/*genetics | 19 | 13.0 |
Complement 4/genetics | 12 | 19.0 |
Cell Differentiation/immunology | 2 | 0.0 |
Melanoma/genetics/*immunology/pathology | 2 | 66.0 |
Australia | 7 | 3.0 |
*Telomere | 3 | 11.0 |
Uveitis/*etiology | 2 | 50.0 |
DNA, Satellite/analysis | 2 | 6.0 |
Tissue Donors/*supply & distribution | 7 | 77.0 |
Blood Group Antigens/*genetics | 5 | 4.0 |
Kidney Failure, Chronic/etiology/*surgery | 2 | 100.0 |
Endothelium/immunology | 4 | 18.0 |
Cervix Neoplasms/*genetics/immunology | 2 | 100.0 |
Methotrexate/*administration & dosage | 2 | 18.0 |
Maternal-Fetal Exchange | 7 | 5.0 |
Algeria/ethnology | 2 | 66.0 |
Italy/ethnology | 4 | 11.0 |
Enhancer Elements (Genetics) | 6 | 1.0 |
Genes, Reporter | 3 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 35 | 4.0 |
*Cell Line | 4 | 8.0 |
Genes, myc | 2 | 0.0 |
Nucleic Acid Hybridization/genetics | 3 | 75.0 |
Kinetics | 28 | 0.0 |
Interleukin-2/pharmacology | 8 | 1.0 |
T-Lymphocytes, Helper-Inducer/drug effects/immunology | 2 | 20.0 |
Taiwan/epidemiology | 2 | 1.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics/*immunology | 3 | 33.0 |
*Homozygote | 6 | 3.0 |
Europe/epidemiology | 2 | 2.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
Actuarial Analysis | 18 | 24.0 |
Busulfan/therapeutic use | 2 | 16.0 |
Methylprednisolone/therapeutic use | 2 | 4.0 |
HLA-B7 Antigen | 15 | 53.0 |
Genetic Vectors | 3 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Haplorhini | 2 | 0.0 |
Plasmids | 5 | 0.0 |
Epitopes/*analysis | 13 | 8.0 |
Receptors, Antigen, T-Cell/*immunology | 5 | 2.0 |
Antigens, CD8/immunology | 3 | 3.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Lymphocyte Activation/drug effects | 5 | 0.0 |
Zambia | 2 | 14.0 |
Base Composition | 2 | 0.0 |
DNA Primers/*genetics | 2 | 20.0 |
Splenectomy | 3 | 4.0 |
MNSs Blood-Group System/genetics | 2 | 18.0 |
Paternity | 4 | 5.0 |
Africa, Eastern | 3 | 60.0 |
Tumor Cells, Cultured/*immunology | 2 | 9.0 |
Concanavalin A/immunology | 2 | 11.0 |
*Evolution | 8 | 4.0 |
Mutagenesis | 3 | 0.0 |
Primates/genetics | 2 | 4.0 |
Epitopes/analysis/*immunology | 2 | 28.0 |
HLA-A Antigens/analysis/*immunology | 4 | 100.0 |
Hybridomas/immunology | 7 | 5.0 |
*HLA-A Antigens | 16 | 84.0 |
*HLA-B Antigens | 31 | 54.0 |
*HLA-DR Antigens | 3 | 21.0 |
Kidney Transplantation/*immunology/mortality | 6 | 66.0 |
Australia/epidemiology | 2 | 3.0 |
Scotland/ethnology | 2 | 50.0 |
HLA Antigens/analysis/*genetics | 27 | 75.0 |
Bone Marrow Transplantation/*adverse effects/immunology | 3 | 27.0 |
Graft Rejection/prevention & control | 3 | 7.0 |
Thyroiditis, Autoimmune/*genetics | 2 | 18.0 |
Adrenal Hyperplasia, Congenital/genetics/*immunology | 2 | 100.0 |
Steroid 21-Hydroxylase/genetics | 5 | 11.0 |
Up-Regulation/immunology | 2 | 1.0 |
Leukemia/mortality/therapy | 3 | 75.0 |
Interferon Type I/*pharmacology | 9 | 18.0 |
Antigenic Variation/*genetics | 2 | 28.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics/immunology | 3 | 30.0 |
Effect Modifiers (Epidemiology) | 2 | 66.0 |
Finland/epidemiology | 4 | 3.0 |
Hypersensitivity, Delayed/immunology | 4 | 6.0 |
Lymphocytes/cytology/immunology | 3 | 13.0 |
Protein Biosynthesis | 12 | 0.0 |
Restriction Mapping | 12 | 0.0 |
Australia/ethnology | 2 | 33.0 |
*Consanguinity | 2 | 8.0 |
Recombination, Genetic/genetics | 2 | 2.0 |
Cornea/immunology | 2 | 40.0 |
Questionnaires | 5 | 0.0 |
Asbestos, Crocidolite/*toxicity | 2 | 100.0 |
Cell Survival/drug effects | 3 | 0.0 |
*Mutagenesis | 2 | 3.0 |
Antigens, Neoplasm/analysis/genetics | 2 | 25.0 |
Carcinoma, Basal Cell/genetics/*immunology | 2 | 100.0 |
Skin Neoplasms/genetics/*immunology | 2 | 50.0 |
Receptors, Antigen, T-Cell/*genetics | 2 | 2.0 |
Great Britain/epidemiology | 4 | 3.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Isoelectric Focusing/*methods | 2 | 5.0 |
Liver Transplantation/*immunology/mortality | 2 | 100.0 |
Major Histocompatibility Complex/*immunology | 5 | 12.0 |
Autoantigens/immunology | 3 | 2.0 |
Peptides/chemistry/immunology | 2 | 5.0 |
Lymphocytes/drug effects | 4 | 5.0 |
Mutagenicity Tests | 2 | 1.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
ABO Blood-Group System/genetics | 4 | 9.0 |
Models, Statistical | 4 | 2.0 |
Rh-Hr Blood-Group System/genetics | 3 | 10.0 |
Hybridomas/*immunology | 5 | 17.0 |
Immunoglobulin G/*immunology | 4 | 4.0 |
Antibody Affinity | 2 | 1.0 |
Graft Rejection/drug therapy | 2 | 33.0 |
Siblings | 3 | 4.0 |
Africa, Southern | 2 | 18.0 |
Complement/genetics | 8 | 29.0 |
DNA/chemistry/genetics/isolation & purification | 2 | 3.0 |
Spondylitis, Ankylosing/*genetics | 5 | 18.0 |
Kuwait | 4 | 16.0 |
*Immunohistochemistry | 2 | 2.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Papua New Guinea | 4 | 17.0 |
17-alpha-Hydroxyprogesterone | 3 | 6.0 |
*Adrenal Hyperplasia, Congenital/*genetics | 2 | 28.0 |
Hydroxyprogesterones/blood | 2 | 4.0 |
Steroid 21-Hydroxylase/*genetics | 3 | 4.0 |
Kidney Transplantation/*immunology/statistics & numerical data | 13 | 76.0 |
Oligonucleotide Probes/*genetics | 2 | 40.0 |
Illinois | 2 | 50.0 |
Receptors, Virus/*metabolism | 2 | 2.0 |
HLA Antigens/*blood/genetics | 2 | 66.0 |
HLA-DR Antigens/*analysis/immunology | 3 | 42.0 |
Chromosome Aberrations | 3 | 0.0 |
X Chromosome | 3 | 0.0 |
Immunoglobulin G/*analysis | 2 | 2.0 |
Switzerland | 2 | 2.0 |
*ATP-Binding Cassette Transporters | 2 | 1.0 |
Lymph Nodes/*immunology/pathology | 2 | 15.0 |
Lymphatic Metastasis | 6 | 0.0 |
Colonic Neoplasms/*immunology | 2 | 8.0 |
Chromosomes, Human | 3 | 5.0 |
Antibodies/blood | 2 | 3.0 |
Ferritin/*blood | 5 | 7.0 |
Iron/*metabolism | 4 | 3.0 |
Washington/epidemiology | 2 | 12.0 |
Kidney Function Tests | 5 | 4.0 |
Cytotoxicity, Immunologic/drug effects | 2 | 1.0 |
Immunoglobulin M/*immunology | 2 | 3.0 |
Antigens, CD/*analysis | 6 | 0.0 |
Antigens, Surface/*analysis | 10 | 5.0 |
*Immunologic Tests | 2 | 28.0 |
Skin/pathology | 4 | 1.0 |
*T-Lymphocytes | 3 | 6.0 |
DNA/analysis/genetics | 2 | 1.0 |
NF-kappa B/metabolism | 2 | 0.0 |
DNA/analysis/*genetics | 2 | 10.0 |
Interferon-gamma, Recombinant/*pharmacology | 5 | 3.0 |
Killer Cells, Lymphokine-Activated/immunology | 2 | 3.0 |
Birth Weight | 3 | 1.0 |
HLA-A3 Antigen/*genetics | 3 | 100.0 |
Cytotoxicity, Immunologic/immunology | 3 | 4.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 10 | 10.0 |
HLA Antigens/analysis/*immunology | 7 | 70.0 |
Isoantibodies/blood | 2 | 8.0 |
Laboratories/standards | 3 | 16.0 |
HLA-B Antigens/analysis/*immunology | 2 | 50.0 |
Keratoplasty, Penetrating/*immunology | 6 | 100.0 |
Graves' Disease/*ethnology/genetics | 2 | 100.0 |
Autoimmune Diseases/genetics/*immunology | 5 | 26.0 |
California | 6 | 12.0 |
*Cause of Death | 2 | 10.0 |
Antigens, Viral/analysis | 2 | 2.0 |
Chromosomes, Human, Pair 6/immunology | 2 | 100.0 |
Sarcoidosis/*genetics | 4 | 25.0 |
Graves' Disease/*genetics | 8 | 21.0 |
Myasthenia Gravis/*genetics | 2 | 33.0 |
*HLA Antigens/genetics | 21 | 84.0 |
Immune Sera/immunology | 8 | 4.0 |
Herpesvirus 4, Human/immunology | 10 | 13.0 |
Intestinal Mucosa/immunology | 2 | 3.0 |
Placenta/immunology | 4 | 16.0 |
Pseudogenes | 6 | 3.0 |
Hepatitis/*genetics/immunology | 2 | 100.0 |
Immunoglobulin A/blood | 2 | 1.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Kidney Transplantation/immunology/*statistics & numerical data | 5 | 50.0 |
Reoperation/statistics & numerical data | 7 | 77.0 |
Antigens, CD1 | 2 | 2.0 |
Epithelium | 2 | 3.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Bronchitis/genetics/*immunology | 2 | 100.0 |
Antilymphocyte Serum/pharmacology | 8 | 66.0 |
Nephrectomy | 3 | 3.0 |
Radioimmunoassay | 14 | 0.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
Y Chromosome | 2 | 2.0 |
Epithelium/immunology/physiology | 2 | 100.0 |
Abortion, Habitual/*immunology/prevention & control | 2 | 100.0 |
*Leukocyte Transfusion | 4 | 50.0 |
Telomere | 2 | 3.0 |
Crossing Over, Genetic | 8 | 10.0 |
Osteosarcoma/*immunology | 2 | 66.0 |
*Genes, Regulator | 2 | 1.0 |
Cell Adhesion/drug effects | 2 | 0.0 |
HLA Antigens/biosynthesis | 2 | 13.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
Microscopy, Electron, Scanning | 4 | 1.0 |
Lymphocytes/ultrastructure | 4 | 9.0 |
Azathioprine/administration & dosage/therapeutic use | 2 | 100.0 |
*Immune Sera | 3 | 17.0 |
Cell Count | 3 | 0.0 |
*Cosmids | 2 | 10.0 |
Hybrid Cells | 4 | 0.0 |
Antigens, CD8/analysis | 3 | 1.0 |
Melanoma/*immunology/therapy | 3 | 33.0 |
Lupus Erythematosus, Systemic/ethnology/*genetics | 2 | 20.0 |
Bone Marrow/pathology | 2 | 0.0 |
HLA-B35 Antigen/blood | 2 | 100.0 |
Hepatitis B/*immunology | 5 | 15.0 |
Intercellular Adhesion Molecule-1 | 4 | 1.0 |
HLA-D Antigens/analysis | 12 | 21.0 |
*Kidney Transplantation/mortality | 3 | 50.0 |
HLA-DP Antigens/analysis | 5 | 35.0 |
Colonic Neoplasms/genetics/*immunology | 2 | 66.0 |
Autoantibodies/*analysis | 8 | 3.0 |
Sibling Relations | 3 | 30.0 |
Sjogren's Syndrome/*genetics | 2 | 20.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Hemoglobins/analysis | 2 | 0.0 |
Multigene Family | 7 | 0.0 |
Antigens, CD8/*immunology | 2 | 3.0 |
HLA-A2 Antigen/genetics/*immunology | 4 | 44.0 |
Antibodies, Antinuclear/*analysis | 3 | 11.0 |
Ribonucleoproteins/*analysis | 2 | 33.0 |
Graves' Disease/*genetics/immunology | 2 | 18.0 |
Cell Adhesion Molecules/*analysis | 2 | 1.0 |
Chromosomes, Fungal | 2 | 3.0 |
*Genes, Structural | 19 | 2.0 |
Clinical Protocols | 4 | 6.0 |
HLA-DP Antigens/analysis/genetics/immunology | 2 | 100.0 |
HLA-DQ Antigens/analysis/genetics/immunology | 2 | 100.0 |
HLA-DR Antigens/analysis/genetics/immunology | 2 | 100.0 |
Neoplasm Recurrence, Local | 5 | 1.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Northern Ireland | 2 | 9.0 |
Immunity, Natural | 6 | 2.0 |
HLA Antigens/analysis/genetics/*immunology | 2 | 66.0 |
Tumor Necrosis Factor-alpha/genetics | 5 | 2.0 |
Cost-Benefit Analysis | 2 | 1.0 |
Histocompatibility Testing/economics | 2 | 100.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Interferons/pharmacology | 4 | 5.0 |
Antilymphocyte Serum/analysis | 6 | 42.0 |
HLA Antigens/analysis/classification | 2 | 40.0 |
Azathioprine/administration & dosage | 4 | 44.0 |
Graft Rejection/*immunology/mortality | 2 | 100.0 |
Prednisolone/administration & dosage | 2 | 2.0 |
Blood Platelets/immunology | 16 | 23.0 |
Forms and Records Control | 2 | 66.0 |
*Platelet Transfusion | 5 | 20.0 |
HLA-DR3 Antigen/*analysis | 2 | 28.0 |
Epidemiologic Methods | 3 | 5.0 |
Behcet Syndrome/*genetics/immunology | 2 | 28.0 |
History, Ancient | 2 | 11.0 |
Arthritis, Rheumatoid/epidemiology/*immunology | 2 | 50.0 |
Hamsters | 4 | 0.0 |
*African Continental Ancestry Group | 13 | 11.0 |
*Transfection | 7 | 2.0 |
Epitopes/analysis | 15 | 6.0 |
Herpesvirus 4, Human/genetics/immunology | 2 | 25.0 |
Multiple Sclerosis/*immunology | 4 | 3.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
Codon | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Endothelium, Corneal/immunology | 2 | 100.0 |
Graft Enhancement, Immunologic | 3 | 33.0 |
Arthritis/*immunology | 4 | 16.0 |
*Immunity, Cellular | 18 | 13.0 |
Yersinia enterocolitica/immunology | 2 | 100.0 |
Crohn Disease/genetics/*immunology | 2 | 66.0 |
Cell Transformation, Neoplastic/genetics/immunology | 2 | 66.0 |
*Mutagenicity Tests | 2 | 25.0 |
Fetus/*immunology | 7 | 14.0 |
Liver/*immunology | 4 | 10.0 |
Diabetes Mellitus, Type 1/*genetics/immunology/physiopathology | 2 | 100.0 |
Hemoglobin A, Glycosylated/analysis | 2 | 0.0 |
Genes, Lethal | 2 | 2.0 |
Hematopoiesis | 2 | 0.0 |
Immunologic Deficiency Syndromes/*surgery | 2 | 100.0 |
Chromosome Deletion | 11 | 1.0 |
*IgA Deficiency | 8 | 44.0 |
Arthritis, Rheumatoid/complications/*immunology | 2 | 33.0 |
Poland | 2 | 1.0 |
Immunosuppression/adverse effects | 2 | 18.0 |
Pulmonary Fibrosis/etiology | 2 | 40.0 |
Diabetes Mellitus, Type 1/*immunology | 6 | 8.0 |
Corticotropin/diagnostic use | 2 | 9.0 |
Immunoglobulins, Heavy-Chain/*analysis | 2 | 40.0 |
beta 2-Microglobulin/*analysis | 6 | 7.0 |
HLA-B Antigens/chemistry/*genetics | 5 | 55.0 |
Antigens, CD4/analysis | 2 | 0.0 |
Cell Separation | 17 | 1.0 |
*Pregnancy Outcome | 2 | 3.0 |
Hemochromatosis/*diagnosis/genetics | 2 | 50.0 |
Glucose Tolerance Test | 2 | 0.0 |
HLA-DR4 Antigen/*analysis | 4 | 44.0 |
Hypertension/*immunology | 2 | 28.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 3 | 3.0 |
Genes, Structural | 31 | 3.0 |
Interleukin-2/analysis | 3 | 7.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
*HLA-DQ Antigens/genetics | 2 | 100.0 |
*HLA-DR Antigens/genetics | 2 | 33.0 |
Histocompatibility Antigens Class II/analysis/genetics | 3 | 75.0 |
Spinocerebellar Degenerations/*genetics | 5 | 29.0 |
Sex Ratio | 2 | 7.0 |
Wegener's Granulomatosis/*genetics | 2 | 33.0 |
African Americans | 3 | 2.0 |
Cell Separation/methods | 2 | 1.0 |
Seasons | 4 | 2.0 |
Graves' Disease/*immunology | 8 | 9.0 |
Arizona | 4 | 13.0 |
Lupus Erythematosus, Systemic/*immunology | 4 | 2.0 |
*Restriction Mapping | 2 | 5.0 |
Benzamides/*pharmacology | 2 | 9.0 |
Niacinamide/*pharmacology | 3 | 30.0 |
Poly(ADP-ribose) Polymerases/*antagonists & inhibitors | 2 | 25.0 |
Multiple Sclerosis/*genetics | 7 | 8.0 |
Electrophoresis | 2 | 0.0 |
Takayasu's Arteritis/*genetics | 2 | 25.0 |
HLA-A Antigens/drug effects/genetics | 2 | 100.0 |
Kidney Transplantation/immunology/*mortality/statistics & numerical data | 3 | 100.0 |
Mitotic Index | 2 | 1.0 |
Kidney Failure, Chronic/mortality/*surgery | 3 | 42.0 |
Postoperative Complications/*mortality | 4 | 44.0 |
Oligonucleotides/chemistry | 2 | 1.0 |
Antigens, Surface/analysis/*genetics | 2 | 20.0 |
Immunologic Techniques | 10 | 3.0 |
Receptors, IgG | 4 | 2.0 |
Antibodies/*blood | 2 | 4.0 |
Cell Cycle | 4 | 0.0 |
DNA/biosynthesis | 5 | 0.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Interferons/*pharmacology | 7 | 9.0 |
Postoperative Complications | 7 | 5.0 |
Lupus Erythematosus, Systemic/genetics/*immunology | 5 | 15.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Antigens, CD8 | 4 | 1.0 |
Antigens, CD20 | 2 | 2.0 |
Antigens, CD36 | 2 | 1.0 |
Antigens, Surface/immunology | 11 | 5.0 |
Interleukin-2/*pharmacology | 2 | 0.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
T-Lymphocytes/drug effects/*immunology | 3 | 2.0 |
Epstein-Barr Virus Nuclear Antigens | 2 | 4.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Thioguanine/pharmacology | 2 | 11.0 |
*Biological Markers | 4 | 3.0 |
Tumor Markers, Biological | 2 | 0.0 |
*Cloning, Molecular | 6 | 1.0 |
Endothelium, Vascular/*immunology | 3 | 3.0 |
Myasthenia Gravis/*immunology | 4 | 17.0 |
*Heterozygote | 2 | 0.0 |
Histocompatibility Antigens Class I/chemistry/genetics/*metabolism | 2 | 25.0 |
*Adrenal Hyperplasia, Congenital | 2 | 9.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
Herpesvirus 4, Human/*immunology | 14 | 20.0 |
Carcinoma, Bronchogenic/*immunology | 2 | 33.0 |
Peripheral Nerves/immunology | 2 | 25.0 |
Cyclosporins/therapeutic use | 16 | 42.0 |
*Antibody Formation | 6 | 6.0 |
*Blood Grouping and Crossmatching | 7 | 41.0 |
*Isoantibodies | 11 | 64.0 |
Isoantibodies/biosynthesis | 3 | 30.0 |
Uveomeningoencephalitic Syndrome/*immunology | 2 | 50.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Immunoglobulin M/biosynthesis | 3 | 3.0 |
Immunologic Capping | 4 | 8.0 |
Brain/immunology | 2 | 7.0 |
Burkitt Lymphoma/*immunology | 4 | 20.0 |
Immunoglobulin G/analysis | 7 | 1.0 |
Cyclosporins/*therapeutic use | 12 | 48.0 |
Kidney/physiology | 2 | 3.0 |
Carcinoma, Squamous Cell/immunology/pathology | 2 | 25.0 |
Cell Transformation, Neoplastic/*immunology | 2 | 33.0 |
HLA-C Antigens/metabolism | 3 | 50.0 |
Choriocarcinoma/*immunology | 5 | 62.0 |
Teratoma/*immunology | 6 | 66.0 |
Monocytes/*immunology | 14 | 3.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Immunoelectrophoresis | 5 | 2.0 |
Molecular Conformation | 4 | 1.0 |
Lymphocytes/*immunology/pathology | 2 | 10.0 |
Tetradecanoylphorbol Acetate/pharmacology | 6 | 0.0 |
Fibroblasts/immunology | 10 | 14.0 |
Dysgammaglobulinemia/genetics/*immunology | 2 | 100.0 |
Immunoglobulin Gm Allotypes/*analysis | 2 | 40.0 |
Immunoglobulins, kappa-Chain/*analysis | 2 | 22.0 |
West Indies | 2 | 25.0 |
Glomerulonephritis, IGA/*immunology | 4 | 22.0 |
Antigens, Differentiation/analysis | 3 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 3 | 0.0 |
Neprilysin | 4 | 5.0 |
Microscopy, Electron | 10 | 0.0 |
Lactoylglutathione Lyase/genetics | 12 | 27.0 |
*Immunosuppression | 7 | 9.0 |
Lymphocytes/pathology | 2 | 2.0 |
Laryngeal Neoplasms/*immunology/pathology | 2 | 50.0 |
Colitis, Ulcerative/*genetics | 3 | 11.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
HLA Antigens/*isolation & purification | 9 | 69.0 |
Isoantibodies | 8 | 32.0 |
HLA-DQ Antigens/*immunology | 2 | 14.0 |
HLA-B Antigens/analysis/immunology | 4 | 80.0 |
HLA-DR Antigens/analysis/immunology | 4 | 21.0 |
*Renal Dialysis | 4 | 0.0 |
Vaccines/*immunology | 2 | 28.0 |
Hydatidiform Mole/*genetics/immunology | 3 | 100.0 |
Uterine Neoplasms/*genetics/immunology | 2 | 100.0 |
Gene Frequency/genetics/immunology | 2 | 50.0 |
*Blood Group Antigens | 3 | 5.0 |
Lymphocytes/*metabolism | 5 | 3.0 |
HLA-C Antigens/analysis/immunology | 3 | 75.0 |
Choriocarcinoma/genetics/*immunology | 3 | 100.0 |
Uterine Neoplasms/genetics/*immunology | 3 | 100.0 |
USSR | 2 | 11.0 |
Electromyography | 2 | 1.0 |
Chloroquine/pharmacology | 3 | 3.0 |
Genetic Markers/analysis | 5 | 19.0 |
Temporal Lobe/*immunology/pathology | 2 | 100.0 |
Minnesota | 3 | 13.0 |
England | 7 | 5.0 |
Antigens, CD3 | 3 | 0.0 |
Cytokines | 2 | 1.0 |
Adrenal Cortex Hormones/*therapeutic use | 2 | 8.0 |
Graves' Disease/complications/*immunology | 2 | 66.0 |
Malaysia | 2 | 5.0 |
*Immunity, Maternally-Acquired | 2 | 15.0 |
Cell Transformation, Viral | 12 | 4.0 |
Dermatitis, Contact/etiology/*immunology | 2 | 66.0 |
Nickel/*adverse effects | 3 | 37.0 |
Bladder/*immunology | 2 | 50.0 |
*Oncogenes | 2 | 0.0 |
Antibodies, Monoclonal/administration & dosage | 2 | 6.0 |
Immunologic Deficiency Syndromes/immunology/*surgery | 2 | 100.0 |
Concanavalin A/pharmacology | 5 | 2.0 |
Interferon Type I, Recombinant/*pharmacology | 2 | 4.0 |
Phytohemagglutinins/pharmacology | 17 | 3.0 |
Lymphotoxin/biosynthesis | 2 | 11.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Teratoma/genetics/*immunology | 2 | 100.0 |
Killer Cells/immunology | 6 | 21.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 10 | 17.0 |
Psoriasis/*genetics/immunology | 2 | 15.0 |
Hemagglutination Tests | 3 | 3.0 |
Polycystic Kidney Diseases/*genetics | 2 | 5.0 |
Autoantibodies | 2 | 6.0 |
HLA-B8 Antigen | 19 | 70.0 |
Czechoslovakia | 3 | 17.0 |
L Cells (Cell Line) | 3 | 1.0 |
HLA Antigens/*analysis/genetics/immunology | 7 | 77.0 |
Immunization, Passive | 4 | 4.0 |
Adenocarcinoma/immunology | 4 | 9.0 |
Transplantation, Isogeneic | 3 | 10.0 |
HLA-D Antigens/*analysis/genetics | 3 | 75.0 |
Epitopes/*analysis/genetics | 2 | 50.0 |
Immune Sera | 22 | 7.0 |
Software | 2 | 0.0 |
Crohn Disease/*genetics | 2 | 5.0 |
Teratoma/*genetics | 2 | 40.0 |
Lymphoma/*immunology | 3 | 9.0 |
Clinical Trials | 4 | 0.0 |
Chromosome Disorders | 3 | 0.0 |
*Genes, Dominant | 4 | 1.0 |
Cyclosporins/administration & dosage | 4 | 66.0 |
Lymphocyte Function-Associated Antigen-1 | 4 | 5.0 |
Hepatitis B/genetics/*immunology | 3 | 100.0 |
Lymphocytes/analysis | 3 | 20.0 |
Chromatography, Gel | 3 | 0.0 |
HLA-B27 Antigen | 19 | 48.0 |
Norway | 6 | 5.0 |
HLA-D Antigens/*analysis | 32 | 52.0 |
T-Lymphocytes/classification/*immunology | 3 | 4.0 |
Parents | 6 | 8.0 |
Graves' Disease/genetics/*immunology | 6 | 66.0 |
Antibodies, Monoclonal/physiology | 8 | 11.0 |
Cytosol/metabolism | 2 | 0.0 |
Interleukin-4 | 2 | 2.0 |
*Nucleic Acid Hybridization | 2 | 3.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Infertility, Male/*immunology | 2 | 25.0 |
Antibodies, Viral/*analysis | 4 | 6.0 |
Simplexvirus/*immunology | 2 | 5.0 |
Antigens, CD5 | 2 | 0.0 |
Receptors, Interleukin-2 | 2 | 1.0 |
Autoantibodies/*biosynthesis | 3 | 5.0 |
Immunoglobulin Idiotypes/*immunology | 2 | 5.0 |
*Cross-Linking Reagents | 3 | 20.0 |
T-Lymphocytes/immunology/*metabolism | 3 | 3.0 |
Autoantibodies/analysis | 11 | 6.0 |
B-Lymphocytes/analysis | 2 | 15.0 |
T-Lymphocytes/analysis | 3 | 13.0 |
Mice, Inbred A | 2 | 3.0 |
Rats, Inbred Strains | 4 | 0.0 |
T-Lymphocytes/classification | 3 | 9.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Phagocytosis | 2 | 0.0 |
Rosette Formation | 28 | 9.0 |
Liver/blood supply | 2 | 13.0 |
Antibodies, Viral/analysis | 9 | 8.0 |
Immunoglobulin M/analysis | 4 | 1.0 |
Hepatitis B Vaccines | 2 | 33.0 |
Viral Hepatitis Vaccines/*immunology | 2 | 40.0 |
HLA-DR4 Antigen | 29 | 49.0 |
Chromosome Banding | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 2 | 1.0 |
Dysgerminoma/*genetics | 2 | 50.0 |
Testicular Neoplasms/*genetics | 2 | 8.0 |
Antigens, Differentiation, T-Lymphocyte | 15 | 5.0 |
Abortion, Habitual/etiology/*immunology | 2 | 66.0 |
*Graft Survival/drug effects | 2 | 100.0 |
B-Lymphocytes/radiation effects | 2 | 40.0 |
Lung Neoplasms/*etiology | 3 | 12.0 |
Tobacco Smoke Pollution/*adverse effects | 3 | 9.0 |
Fetus | 5 | 0.0 |
HLA-DR6 Antigen | 3 | 100.0 |
Complement 4a | 7 | 11.0 |
Complement 4b | 8 | 8.0 |
HLA-DR5 Antigen | 11 | 68.0 |
Steroid Hydroxylases/*deficiency | 5 | 17.0 |
Acquired Immunodeficiency Syndrome/complications/*immunology | 2 | 8.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
Homosexuality | 3 | 2.0 |
Lupus Erythematosus, Discoid/*immunology | 2 | 28.0 |
Complement/*genetics | 7 | 12.0 |
Tissue and Organ Procurement/organization & administration | 2 | 50.0 |
Diabetes Mellitus, Type 1/drug therapy/*immunology | 3 | 75.0 |
Cyclosporins/adverse effects/therapeutic use | 3 | 100.0 |
Kidney/drug effects | 2 | 4.0 |
Islets of Langerhans/*immunology | 4 | 11.0 |
*Graft Enhancement, Immunologic | 3 | 75.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 3 | 1.0 |
Egypt | 5 | 11.0 |
Lymphoma, Non-Hodgkin/therapy | 2 | 8.0 |
Birth Intervals | 3 | 60.0 |
*Fertility | 2 | 10.0 |
HLA Antigens/*analysis/classification/genetics | 2 | 100.0 |
*Graft vs Host Reaction | 3 | 37.0 |
HLA-DR2 Antigen | 9 | 47.0 |
Twins, Monozygotic | 4 | 5.0 |
Receptors, Interferon | 2 | 10.0 |
*ABO Blood-Group System | 7 | 18.0 |
Antibodies, Monoclonal/*physiology | 6 | 15.0 |
HLA-A2 Antigen | 24 | 77.0 |
Influenza A Virus, Human/immunology | 5 | 20.0 |
Antigens, Surface/metabolism | 2 | 1.0 |
Histocompatibility Antigens/*metabolism | 2 | 25.0 |
Ploidies | 2 | 0.0 |
Peptide Fragments/therapeutic use | 2 | 22.0 |
Antigens, Differentiation/*immunology | 2 | 1.0 |
Antigens, Surface/*immunology | 15 | 9.0 |
Thyroid Gland/*immunology | 2 | 3.0 |
ABO Blood-Group System/*genetics | 3 | 6.0 |
Abortion, Spontaneous | 3 | 11.0 |
Hydatidiform Mole/genetics/*immunology | 3 | 100.0 |
DNA Restriction Enzymes/metabolism | 5 | 6.0 |
New York City | 3 | 10.0 |
HLA Antigens/*analysis/classification | 5 | 71.0 |
Nasopharyngeal Neoplasms/*immunology | 3 | 33.0 |
*Immunization | 9 | 20.0 |
Postoperative Complications/etiology | 2 | 5.0 |
*Genes | 6 | 2.0 |
Endocrine System Diseases/genetics/*immunology | 2 | 66.0 |
DNA/*isolation & purification | 2 | 5.0 |
Histocompatibility Antigens Class II | 19 | 43.0 |
Lewis Blood-Group System/*immunology | 2 | 22.0 |
Isoantigens/*analysis | 6 | 27.0 |
Skin Diseases/*immunology | 4 | 18.0 |
Leukemia/*immunology | 5 | 12.0 |
1-Deoxynojirimycin | 2 | 25.0 |
Tunicamycin/pharmacology | 4 | 5.0 |
Liver Diseases/immunology | 2 | 13.0 |
Hepatitis B Core Antigens/analysis | 4 | 44.0 |
Liver/immunology | 4 | 8.0 |
Cell Transformation, Neoplastic/immunology | 2 | 13.0 |
Mitomycins/pharmacology | 3 | 10.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
North Carolina | 2 | 8.0 |
Fatty Liver, Alcoholic/immunology | 2 | 100.0 |
Hepatitis, Alcoholic/immunology | 2 | 50.0 |
Liver Cirrhosis, Alcoholic/immunology | 3 | 100.0 |
Liver Diseases, Alcoholic/genetics/*immunology | 2 | 100.0 |
Scotland | 2 | 5.0 |
Immunodiffusion | 3 | 1.0 |
*Ribonucleoproteins | 2 | 5.0 |
Complement 2/*genetics | 4 | 8.0 |
Enzyme Precursors/*genetics | 16 | 14.0 |
Lactoylglutathione Lyase/*genetics | 12 | 28.0 |
Lyases/*genetics | 12 | 24.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Transferrin/metabolism | 2 | 1.0 |
Hepatitis B Surface Antigens/*analysis | 2 | 6.0 |
Alcohol Drinking | 2 | 1.0 |
Genes, Recessive | 7 | 1.0 |
HLA Antigens/*classification/immunology | 2 | 100.0 |
Alcoholism/complications | 2 | 9.0 |
Prednisone/administration & dosage | 4 | 4.0 |
Isoantibodies/analysis | 10 | 45.0 |
Outcome and Process Assessment (Health Care) | 4 | 19.0 |
Drug Evaluation | 2 | 0.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Antigen-Antibody Complex/*analysis | 2 | 1.0 |
Immunoglobulins/analysis | 4 | 1.0 |
*Phagocytosis | 3 | 2.0 |
Down Syndrome/*genetics | 2 | 2.0 |
RNA, Messenger/*genetics | 6 | 1.0 |
Antilymphocyte Serum/*analysis | 5 | 55.0 |
Antigen-Antibody Complex | 6 | 3.0 |
Sicily | 2 | 10.0 |
*Maternal-Fetal Exchange | 2 | 5.0 |
Lupus Erythematosus, Systemic/*genetics/immunology | 3 | 6.0 |
Transplantation, Homologous/adverse effects/mortality | 2 | 50.0 |
Leukemia, Lymphocytic/immunology | 7 | 26.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 7 | 4.0 |
Smoking | 2 | 0.0 |
DNA Restriction Enzymes/diagnostic use | 4 | 10.0 |
Immune Tolerance | 5 | 1.0 |
*Reproduction | 2 | 10.0 |
Histocompatibility Antigens/*analysis | 17 | 34.0 |
*Preoperative Care | 2 | 10.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 13 | 28.0 |
*HLA-D Antigens/genetics | 2 | 50.0 |
Erythrocytes/immunology | 6 | 2.0 |
HLA Antigens/analysis/*isolation & purification | 2 | 100.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Immunoglobulin M/immunology | 3 | 2.0 |
Diabetes Mellitus, Type 1/*genetics | 4 | 1.0 |
Periodontitis/*immunology | 2 | 11.0 |
*Blood Preservation | 2 | 3.0 |
Adenomatous Polyposis Coli/*genetics | 2 | 3.0 |
Antigen-Antibody Complex/analysis | 5 | 4.0 |
Arthritis, Juvenile Rheumatoid/*immunology | 2 | 10.0 |
Complement 3d | 2 | 2.0 |
Receptors, Complement 3b | 3 | 0.0 |
Complement 2/genetics | 8 | 16.0 |
Immunoglobulin Gm Allotypes/*genetics | 3 | 33.0 |
Myasthenia Gravis/*genetics/immunology | 2 | 16.0 |
Arthritis, Rheumatoid/immunology | 4 | 4.0 |
Coombs' Test | 3 | 10.0 |
Complement 4/immunology | 2 | 5.0 |
Gold Sodium Thiomalate/*adverse effects/therapeutic use | 2 | 100.0 |
Demography | 2 | 1.0 |
Immunoglobulin Allotypes/genetics | 2 | 11.0 |
H-2 Antigens/*genetics | 4 | 40.0 |
Inflammation | 3 | 0.0 |
Glomerulonephritis/*immunology | 3 | 7.0 |
L Cells (Cell Line)/immunology | 5 | 33.0 |
Glycoproteins/*pharmacology | 3 | 3.0 |
Tumor Necrosis Factor-alpha | 6 | 3.0 |
Myasthenia Gravis/genetics/*immunology | 2 | 40.0 |
Arthritis, Rheumatoid/*immunology | 6 | 2.0 |
*Parents | 4 | 40.0 |
Hungary | 4 | 7.0 |
Immunoglobulin G/genetics | 2 | 5.0 |
Graft Rejection/drug effects | 3 | 50.0 |
Antigens, Differentiation, B-Lymphocyte | 2 | 5.0 |
Austria | 5 | 9.0 |
Alaska | 2 | 22.0 |
Interferon Type I/immunology | 2 | 33.0 |
Antibodies, Antinuclear/analysis | 4 | 5.0 |
Thymus Gland/immunology | 2 | 3.0 |
Arthritis, Juvenile Rheumatoid/*genetics/immunology | 2 | 40.0 |
HLA-DR1 Antigen | 6 | 16.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Complement 2/analysis | 2 | 6.0 |
*Pedigree | 2 | 6.0 |
Inflammation/immunology | 2 | 1.0 |
Asbestosis/*immunology | 2 | 66.0 |
Interferon Type II/physiology | 3 | 3.0 |
Hemagglutination | 2 | 5.0 |
Epitopes/genetics/*immunology | 2 | 14.0 |
H-2 Antigens/genetics/*immunology | 2 | 33.0 |
Cytoplasm/immunology | 2 | 2.0 |
Dermatitis, Contact/*immunology | 5 | 41.0 |
Antibodies, Anti-Idiotypic/immunology | 3 | 7.0 |
Interleukin-2 | 3 | 17.0 |
Endothelium/*immunology | 3 | 50.0 |
Glycoproteins/*immunology | 2 | 2.0 |
Interferon Type II/*immunology | 2 | 5.0 |
Germany/ethnology | 2 | 15.0 |
Antigens, Viral/*analysis | 2 | 4.0 |
Histocytochemistry | 6 | 0.0 |
HLA-DP Antigens | 12 | 52.0 |
Hepatitis B Surface Antigens/immunology | 2 | 8.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Deltaretrovirus/immunology | 2 | 22.0 |
Hepatitis B e Antigens/analysis | 2 | 13.0 |
*Blood Transfusion/adverse effects | 3 | 50.0 |
*Tissue Donors/psychology | 2 | 100.0 |
Wisconsin | 2 | 16.0 |
Jews | 7 | 10.0 |
Diabetes Mellitus, Type 1/immunology | 3 | 17.0 |
Interferon Type I/pharmacology | 2 | 4.0 |
Lectins/pharmacology | 2 | 5.0 |
Phytohemagglutinins/*pharmacology | 3 | 8.0 |
Cornea/cytology/*immunology | 2 | 100.0 |
Alberta | 2 | 22.0 |
Hemochromatosis/blood/*genetics | 2 | 22.0 |
Neuroblastoma/immunology | 3 | 50.0 |
Ethers/pharmacology | 2 | 10.0 |
Ionomycin | 2 | 8.0 |
Receptors, Transferrin | 2 | 10.0 |
*Chromosomes, Human, 6-12 and X | 26 | 18.0 |
Epitopes/analysis/genetics | 2 | 66.0 |
HLA-A1 Antigen | 7 | 77.0 |
Liver Cirrhosis, Alcoholic/genetics/*immunology | 2 | 100.0 |
Receptors, Fc/immunology | 3 | 6.0 |
Leukemia, Myelocytic, Acute/immunology | 2 | 15.0 |
Gold/adverse effects/therapeutic use | 2 | 100.0 |
Penicillamine/adverse effects/therapeutic use | 2 | 66.0 |
Receptors, Cholinergic/*immunology | 2 | 10.0 |
Immunologic Deficiency Syndromes/immunology | 3 | 17.0 |
Lymphocytes/classification/*immunology | 3 | 15.0 |
HLA Antigens/analysis/*genetics/immunology | 4 | 100.0 |
Factor XIII/*genetics | 2 | 12.0 |
Transglutaminases | 2 | 25.0 |
T-Lymphocytes/*cytology/immunology | 2 | 4.0 |
Diabetes Mellitus, Type 1/genetics/immunology | 2 | 16.0 |
Leukemia/immunology | 4 | 12.0 |
Chile | 2 | 3.0 |
Immunoglobulin Allotypes/*immunology | 2 | 25.0 |
Immunoglobulin G/*genetics | 3 | 13.0 |
Antigens, Surface/analysis/*immunology | 2 | 16.0 |
Immunochemistry | 2 | 0.0 |
Glioma/*immunology | 2 | 13.0 |
Placental Extracts/immunology | 2 | 66.0 |
*Pregnancy | 4 | 2.0 |
Adsorption | 2 | 1.0 |
Membrane Proteins/immunology | 5 | 9.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Endothelium/physiology | 2 | 13.0 |
Mice, Inbred BALB C/immunology | 4 | 12.0 |
Societies, Medical | 3 | 10.0 |
Histocompatibility Antigens/immunology | 2 | 11.0 |
Blood Group Antigens | 2 | 5.0 |
Antibody-Dependent Cell Cytotoxicity | 12 | 14.0 |
Isoantigens/genetics | 3 | 15.0 |
DNA/metabolism | 4 | 0.0 |
Horses | 2 | 1.0 |
Sheep | 4 | 0.0 |
Pemphigus/*genetics/immunology | 2 | 50.0 |
Gamma Rays | 2 | 0.0 |
Epitopes/analysis/genetics/*immunology | 2 | 100.0 |
Spleen/cytology | 2 | 1.0 |
Freezing | 5 | 5.0 |
*Immunogenetics | 2 | 16.0 |
Jews/*genetics | 2 | 1.0 |
Hybrid Cells/immunology | 3 | 37.0 |
Antibodies/*immunology | 2 | 1.0 |
HLA-DR7 Antigen | 4 | 30.0 |
*Cytotoxicity Tests, Immunologic | 4 | 40.0 |
Cell Membrane/ultrastructure | 2 | 4.0 |
*Cell Transformation, Viral | 7 | 4.0 |
*Antigen-Antibody Reactions | 3 | 7.0 |
*Models, Biological | 2 | 1.0 |
Pemphigus/immunology | 2 | 22.0 |
Skin/*immunology | 3 | 2.0 |
Tetanus Toxoid/*immunology | 2 | 12.0 |
T-Lymphocytes, Cytotoxic/classification/*immunology | 2 | 13.0 |
Breast Neoplasms/*immunology/pathology | 2 | 8.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
Graft Survival/*drug effects | 2 | 10.0 |
Arthritis, Rheumatoid/complications | 2 | 28.0 |
Sjogren's Syndrome/complications/*genetics/immunology | 2 | 100.0 |
Mathematics | 6 | 3.0 |
T-Lymphocytes/*classification/immunology | 2 | 7.0 |
Pokeweed Mitogens/pharmacology | 6 | 7.0 |
Multiple Sclerosis/genetics/*immunology | 2 | 10.0 |
Stomatitis, Aphthous/*immunology | 2 | 33.0 |
Genetic Code | 3 | 7.0 |
Histocompatibility Antigens/analysis | 2 | 3.0 |
Pre-Eclampsia/*immunology | 2 | 14.0 |
DNA, Recombinant/analysis | 2 | 10.0 |
Rabbits/*immunology | 2 | 40.0 |
Complement 4/deficiency/*genetics | 2 | 14.0 |
Microsomes/immunology | 2 | 8.0 |
Thyroglobulin/immunology | 2 | 3.0 |
Thyroid Gland/immunology | 2 | 4.0 |
Antigens, Surface/*genetics | 3 | 4.0 |
Skin Diseases/genetics/*immunology | 2 | 100.0 |
B-Lymphocytes/*immunology/ultrastructure | 3 | 33.0 |
Immunoglobulins, Surface/analysis | 4 | 8.0 |
Phorbols/*pharmacology | 2 | 5.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Tuberculin/*immunology | 2 | 11.0 |
Receptors, Complement/analysis | 2 | 3.0 |
Receptors, Fc/analysis | 2 | 3.0 |
Burkitt Lymphoma | 3 | 3.0 |
Antigens/immunology | 3 | 2.0 |
Hybrid Cells/*immunology | 7 | 53.0 |
Chorion/immunology | 2 | 100.0 |
Placenta/*immunology | 4 | 19.0 |
Neuraminidase | 2 | 5.0 |
Autoimmune Diseases/genetics | 2 | 7.0 |
Histocompatibility Antigens Class II/analysis/*genetics | 2 | 50.0 |
Sarcoma, Kaposi/*immunology | 2 | 40.0 |
Kidney Neoplasms/*immunology | 4 | 14.0 |
Leukemia, Lymphocytic/*immunology | 4 | 13.0 |
beta 2-Microglobulin/*genetics | 6 | 31.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Histocompatibility Antigens Class II/analysis/immunology | 3 | 33.0 |
Bacteria/*immunology | 2 | 11.0 |
T-Lymphocytes, Suppressor-Effector/cytology/*immunology | 2 | 28.0 |
Melanoma/*immunology/pathology | 2 | 8.0 |
*Jews | 3 | 6.0 |
Leukemia, Lymphocytic | 4 | 40.0 |
*Protein Biosynthesis | 2 | 0.0 |
Antigens/analysis | 2 | 1.0 |
Histocompatibility Antigens Class II/*analysis/immunology | 3 | 37.0 |
Oligosaccharides/metabolism | 2 | 4.0 |
Peptides/analysis | 5 | 6.0 |
Precipitation | 5 | 3.0 |
Dysgammaglobulinemia/*immunology | 2 | 33.0 |
*Christianity | 2 | 25.0 |
Blood Glucose/analysis | 4 | 0.0 |
Immunoglobulin Allotypes/analysis | 2 | 22.0 |
Melanocytes/*immunology | 2 | 66.0 |
Neoplasm Proteins/*analysis | 4 | 1.0 |
Skin Neoplasms/*immunology | 2 | 5.0 |
T-Lymphocytes/*classification | 3 | 7.0 |
Germany, West | 4 | 8.0 |
Haemophilus Infections/genetics/*immunology | 2 | 100.0 |
Epidermis/cytology | 2 | 5.0 |
*Antilymphocyte Serum | 3 | 100.0 |
Kidney Glomerulus/pathology | 3 | 6.0 |
Immunoglobulins, Fab | 4 | 7.0 |
Kidney/*immunology | 2 | 14.0 |
Hemolytic Plaque Technique | 3 | 5.0 |
T-Lymphocytes/*immunology/radiation effects | 2 | 18.0 |
*Registries/statistics & numerical data | 2 | 50.0 |
Thyroiditis/immunology | 3 | 50.0 |
Polynesia | 3 | 23.0 |
Hypothyroidism/congenital/genetics/*immunology | 2 | 100.0 |
*Coombs' Test | 2 | 20.0 |
*Lymphocyte Cooperation | 4 | 14.0 |
Antibody-Producing Cells/immunology | 2 | 8.0 |
Epitopes/*genetics/immunology | 3 | 21.0 |
*Aging | 4 | 2.0 |
Cytotoxicity, Immunologic/*drug effects | 3 | 4.0 |
Newfoundland | 2 | 14.0 |
Chromosomes, Human, 6-12 and X | 8 | 18.0 |
*HLA Antigens/analysis | 25 | 71.0 |
Papain | 3 | 30.0 |
Antigens, Surface | 7 | 12.0 |
Detergents | 3 | 2.0 |
Histocompatibility Antigens Class II/*isolation & purification | 2 | 66.0 |
Spleen/immunology | 6 | 3.0 |
Sarcoidosis/*immunology | 3 | 13.0 |
Glomerulonephritis/genetics/*immunology | 4 | 66.0 |
Hemolysis | 3 | 0.0 |
Neuraminidase/analysis | 2 | 100.0 |
Cricetulus | 2 | 0.0 |
Interferon Type I/physiology | 2 | 25.0 |
Leukemia, Myeloid/*immunology | 3 | 7.0 |
Glomerulonephritis, IGA/*classification/genetics/immunology/mortality | 2 | 100.0 |
Hematuria/etiology | 2 | 16.0 |
Immunoglobulin Inv Allotypes/*genetics | 2 | 66.0 |
Kidney Failure, Chronic/etiology | 3 | 11.0 |
Antibodies, Neoplasm/immunology | 3 | 8.0 |
Bladder Neoplasms/*immunology | 5 | 23.0 |
Carcinoma, Transitional Cell/*immunology | 5 | 55.0 |
Antibodies, Anti-Idiotypic/analysis | 3 | 11.0 |
*Antibody-Dependent Cell Cytotoxicity | 4 | 8.0 |
Cell Membrane/immunology/ultrastructure | 2 | 16.0 |
Epithelium/immunology/ultrastructure | 2 | 66.0 |
Dermatitis, Occupational/*immunology | 2 | 100.0 |
HLA Antigens/*genetics/isolation & purification | 2 | 50.0 |
Lymphoma/immunology | 2 | 6.0 |
Atrophy | 2 | 1.0 |
Umbilical Veins/*immunology | 2 | 100.0 |
Killer Cells/*immunology | 3 | 8.0 |
Celiac Disease/complications/*immunology | 2 | 100.0 |
Graft vs Host Reaction | 3 | 27.0 |
Guinea Pigs | 2 | 0.0 |
beta 2-Microglobulin/isolation & purification | 2 | 100.0 |
Measles virus/*immunology | 3 | 25.0 |
Herpesviridae Infections/*immunology | 2 | 20.0 |
Membrane Proteins/*isolation & purification | 2 | 25.0 |
Diabetes Mellitus/*immunology | 3 | 33.0 |
Hybridomas | 2 | 1.0 |
Cell Membrane/*immunology | 2 | 11.0 |
Complement/*immunology | 2 | 1.0 |
*Rosette Formation | 2 | 4.0 |
Postoperative Complications/mortality | 2 | 28.0 |
Beta-Globulins/*immunology | 6 | 75.0 |
Autoantibodies/immunology | 3 | 2.0 |
Receptors, Cholinergic/immunology | 2 | 11.0 |
Complement/analysis | 3 | 2.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Diabetes Mellitus/drug therapy/genetics/*immunology | 2 | 100.0 |
Insulin/therapeutic use | 4 | 3.0 |
Thymus Gland/*immunology | 2 | 3.0 |
Beta-Globulins/*analysis | 3 | 7.0 |
Immune Sera/pharmacology | 11 | 11.0 |
beta 2-Microglobulin/*analysis/immunology | 2 | 66.0 |
Chromosomes, Human, 13-15 | 2 | 25.0 |
Space-Time Clustering | 2 | 33.0 |
Infectious Mononucleosis/*immunology | 5 | 26.0 |
Immunologic Deficiency Syndromes/complications/*immunology | 2 | 100.0 |
Antilymphocyte Serum/*pharmacology | 3 | 33.0 |
Immunologic Deficiency Syndromes/*immunology | 2 | 5.0 |
Absorption | 17 | 13.0 |
Sialic Acids/analysis | 2 | 9.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Amniotic Fluid/cytology/*immunology | 2 | 100.0 |
Immunologic Deficiency Syndromes/*therapy | 2 | 28.0 |
Lectins/immunology | 2 | 12.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
Hybrid Cells/physiology | 2 | 7.0 |
Hypertension/etiology | 2 | 4.0 |
Immunoglobulin A/*analysis | 2 | 3.0 |
Immune Sera/*immunology | 2 | 8.0 |
Membrane Proteins/*immunology | 2 | 3.0 |
Phosphoglucomutase/*genetics | 3 | 2.0 |
Glycoproteins/*biosynthesis | 2 | 4.0 |
Membrane Proteins/*biosynthesis | 3 | 5.0 |
Isoantigens/*genetics | 2 | 20.0 |
Beta-Globulins/*genetics | 4 | 57.0 |
Burkitt Lymphoma/*genetics | 2 | 6.0 |
Liver Cirrhosis, Biliary/*immunology | 2 | 5.0 |
*H-2 Antigens | 3 | 60.0 |
Spondylitis, Ankylosing/immunology | 5 | 38.0 |
Purpura, Thrombocytopenic/genetics/*immunology | 3 | 100.0 |
Circular Dichroism | 2 | 0.0 |
*Hispanic Americans | 2 | 16.0 |
Minor Histocompatibility Loci | 2 | 100.0 |
Blood Group Incompatibility/immunology | 2 | 33.0 |
Thyroiditis, Autoimmune/*immunology | 2 | 2.0 |
Polyethylene Glycols/pharmacology | 2 | 4.0 |
*Histocompatibility Antigens Class II/genetics | 4 | 66.0 |
Immunoglobulins/genetics | 2 | 5.0 |
Membrane Proteins | 2 | 5.0 |
Immunoglobulin E/analysis | 2 | 3.0 |
Dysgerminoma/*immunology | 2 | 100.0 |
*Receptors, Fc | 2 | 28.0 |
*HLA Antigens/immunology | 2 | 100.0 |
Immunoglobulin Fragments | 2 | 22.0 |
New York | 2 | 9.0 |
Diabetes Mellitus/*genetics | 2 | 6.0 |
Cell-Free System | 2 | 0.0 |
Chemistry | 3 | 1.0 |
Translocation, Genetic | 2 | 0.0 |
Histocompatibility Antigens/*immunology | 6 | 25.0 |
Diabetes Mellitus/genetics/*immunology | 2 | 33.0 |
Antibodies, Viral/biosynthesis | 2 | 5.0 |
Rubella/*immunology | 2 | 66.0 |
Rubella virus/immunology | 2 | 33.0 |
Aortic Arch Syndromes/*genetics | 2 | 100.0 |
Immunoglobulin M/deficiency | 2 | 28.0 |
Alveolitis, Extrinsic Allergic/*immunology | 2 | 18.0 |
Schizophrenia, Paranoid/genetics | 2 | 66.0 |
Mitogens/*pharmacology | 2 | 1.0 |
Psoriasis/immunology | 2 | 13.0 |
Blood | 2 | 1.0 |
Immunoglobulin G | 6 | 4.0 |
Papain/pharmacology | 3 | 30.0 |
Staphylococcal Protein A/metabolism | 3 | 18.0 |
Beta-Globulins/*metabolism | 2 | 18.0 |
Immunoglobulins, Heavy-Chain/immunology | 2 | 20.0 |
Nitrobenzenes/*immunology | 5 | 71.0 |
Trinitrobenzenes/*immunology | 4 | 80.0 |
Hylobates | 2 | 15.0 |
Immunoglobulins/*genetics | 2 | 4.0 |
Melanoma/immunology | 3 | 8.0 |
Diabetes Mellitus/*genetics/immunology | 2 | 50.0 |
*Histocompatibility Antigens | 40 | 54.0 |
T-Lymphocytes/drug effects/immunology | 2 | 2.0 |
Computers | 5 | 10.0 |
*Isoantigens | 11 | 68.0 |
*Population | 2 | 28.0 |
Carcinoma/immunology | 2 | 13.0 |
beta 2-Microglobulin | 4 | 57.0 |
Mice, Inbred C3H | 2 | 0.0 |
Testicular Neoplasms/*immunology | 2 | 40.0 |
Macaca/*immunology | 2 | 25.0 |
Macaca mulatta/*immunology | 2 | 14.0 |
Autoradiography | 2 | 0.0 |
Membrane Proteins/*metabolism | 4 | 0.0 |
Surface Properties | 2 | 1.0 |
Thymus Gland/transplantation | 2 | 28.0 |
Membrane Lipids | 2 | 33.0 |
*Antibodies | 6 | 12.0 |
Lactoylglutathione Lyase | 2 | 100.0 |
Adrenal Hyperplasia, Congenital/*genetics | 2 | 8.0 |
Anemia, Aplastic/*immunology | 2 | 20.0 |
H-2 Antigens | 2 | 20.0 |
*Antigens, Surface | 2 | 2.0 |
*Immunoglobulin A | 3 | 21.0 |
Complement | 5 | 11.0 |
Membrane Proteins/biosynthesis | 2 | 3.0 |
Tissue Survival | 2 | 40.0 |
Kidney Glomerulus/immunology | 2 | 6.0 |
Psoriasis/genetics/*immunology | 2 | 66.0 |
*Immunologic Memory | 2 | 1.0 |
Insulin/*therapeutic use | 2 | 2.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Immune Sera/*pharmacology | 3 | 25.0 |
Psoriasis/*immunology | 2 | 11.0 |
Immunoglobulins | 2 | 8.0 |
Antigens, Neoplasm | 3 | 7.0 |
Dementia/*immunology | 2 | 50.0 |
Diabetes Complications | 2 | 1.0 |
Agammaglobulinemia/immunology | 2 | 15.0 |
*HLA Antigens/*analysis | 2 | 100.0 |
Complement 2/*deficiency | 4 | 7.0 |
Immunoglobulin M | 2 | 6.0 |
Diabetes Mellitus/immunology | 2 | 33.0 |
Dinitrobenzenes/immunology | 2 | 33.0 |
Skin Transplantation | 2 | 7.0 |
Complement 3/*analysis | 2 | 2.0 |
*Skin Transplantation | 3 | 15.0 |
*Rh-Hr Blood-Group System | 2 | 6.0 |
Scleroderma, Systemic/*immunology | 2 | 7.0 |
Antigens, Neoplasm/isolation & purification | 2 | 33.0 |
*HLA Antigens/isolation & purification | 2 | 66.0 |
Complement/*analysis | 2 | 1.0 |
Immune Adherence Reaction | 2 | 4.0 |
Thailand/epidemiology | 2 | 3.0 |
*Immunoglobulins, Fc | 2 | 33.0 |
Diabetes Mellitus/drug therapy/*immunology | 2 | 100.0 |
Insulin/*immunology/therapeutic use | 2 | 66.0 |
Crosses, Genetic | 2 | 0.0 |
*Histocompatibility Antigens/analysis | 12 | 80.0 |
Histocompatibility Antigens/*isolation & purification | 4 | 66.0 |
*Properdin | 2 | 50.0 |
Genetics, Medical | 2 | 8.0 |
Internet | 2 | 2.0 |
*Lactoylglutathione Lyase | 2 | 50.0 |
*Lyases | 2 | 40.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Transplantation Conditioning/methods | 2 | 9.0 |